Healthcare & Life Sciences — April 18, 2026

Public Complaint Form for Violations Against Licensed Optometrists

The Nevada State Board of Optometry has published a public complaint form allowing individuals to file complaints against licensed optometrists for alleged violations of NRS Chapter 636 or NAC 636. Complainants must provide facts with particularity, cite specific statutes, and submit credible evidence supporting their claims or the complaint will be rejected.

Turkish Version of the Eksterociptive Body Awareness Questionnaire Validation Study NCT07536685

The National Institutes of Health registered an observational study (NCT07536685) to validate the Turkish version of the Eksterociptive Body Awareness Questionnaire (EBA-Q). The study involves 70 healthy adult participants who will complete a survey using the questionnaire. The study aims to establish the validity and reliability of the instrument for use in Turkish research.

AI-ECG Observational Study for Acute Aortic Dissection

NIH registered a prospective multicenter observational study (NCT07536932) evaluating an AI-ECG model for diagnosing acute type A aortic dissection in emergency department patients with chest pain. The study will enroll adults at five tertiary hospitals and compare AI model predictions against CTA-confirmed diagnoses. Clinical and ECG data will be collected as part of standard care to assess diagnostic performance across centers.

Measurement of Ocular Blood Flow and Retinal Oxygen Extraction in Diabetic Patients

NIH has registered a clinical trial (NCT07536516) investigating the impact of GLP-1 receptor agonists (semaglutide, liraglutide) and GIP/GLP-1 dual agonists (tirzepatide) on ocular blood flow and retinal function in diabetic patients. The study will use Laser Speckle Flowgraphy (LSFG), Optical Coherence Tomography (OCT), and Optical Coherence Tomography Angiography (OCT-A) as diagnostic interventions. The trial focuses on patients with diabetes mellitus to evaluate potential neuroprotective effects on retinal microvasculature.

Telerehabilitation vs Conventional Rehab Non-Inferiority Trial for Subacromial Pain

NIH has registered a clinical trial (NCT07536009) on ClinicalTrials.gov evaluating whether a telerehabilitation program is non-inferior to conventional in-person physical therapy for patients with subacromial pain syndrome. The prospective, randomized, parallel-group, single-center controlled non-inferiority trial will measure primary outcome of shoulder function using the QuickDASH questionnaire at 12 weeks. Secondary outcomes include pain intensity, range of motion, treatment adherence, and long-term functional outcomes.

ALN-4915 Phase 1 Trial, Healthy Volunteers

Alnylam has registered a Phase 1 clinical trial for ALN-4915 on ClinicalTrials.gov (NCT07535606). The study will evaluate safety, tolerability, pharmacodynamics, and pharmacokinetics of ALN-4915 in adult healthy volunteers. The trial involves approximately 60 participants receiving ALN-4915 or placebo.

Open Label SKY-0515 Huntington's Disease Trial Phase 2

NIH ClinicalTrials.gov registered a Phase 2 open-label extension study (NCT07537075) for SKY-0515, an oral medication being evaluated for Huntington's Disease. The trial will enroll adults aged 25 and older with genetically confirmed HD to assess whether SKY-0515 can lower harmful proteins associated with the disease and improve symptoms. The study is registered as Phase 2 with an anticipated start date.

Observational BMPR2-Activin Pathway Study in Group II Pulmonary Hypertension

The NIH registered a prospective observational study (NCT07537517) on ClinicalTrials.gov evaluating the BMPR2-activin signaling pathway in Group II pulmonary hypertension associated with left heart disease. The study will enroll 150 heart failure patients undergoing hemodynamic assessment with a 1-year follow-up, plus a nested substudy of 40 heart transplant candidates for vascular morphometric analysis. Results may inform PH-LHD classification, precision-medicine models, and targeted therapies such as activin inhibitors.

ESPB vs ICNB Postoperative Pain VATS Randomized Trial

NIH's ClinicalTrials.gov has registered study NCT07535697, a prospective randomized trial comparing ultrasound-guided erector spinae plane block (ESPB) to thoracoscopically-guided intercostal nerve block (ICNB) for postoperative pain management in adults undergoing video-assisted thoracoscopic surgery (VATS). The study will evaluate analgesic consumption over 24 hours, pain levels at predefined time points, and procedure duration to determine whether ESPB provides comparable analgesia to ICNB.

KIA-Korekt: Staged Unimodal-to-Multimodal AI Evaluation for Perioperative Risk Prediction in Colorectal Cancer

NIH ClinicalTrials.gov registered NCT07537491 (KIA-Korekt study), an observational study conducted at University Hospital Brandenburg investigating whether multimodal AI analysis of medical imaging can predict perioperative complications in colorectal cancer patients. The study integrates digital histopathology (H&E-WSIs), CT/MRI radiomics, and multiplex tissue imaging across a retrospective cohort of approximately 750 CRC patients (2011–2021) and a prospective validation cohort of approximately 210 patients (2026–2028).

Phase 2 CAOP Trial for Peripheral T-Cell Lymphoma

NIH registered a Phase 2 clinical trial (NCT07535762) evaluating CAOP (Aclarubicin, Cyclophosphamide, Vincristine, Prednisone) in elderly patients with newly diagnosed Peripheral T-Cell Lymphoma (PTCL). The trial targets three subtypes: PTCL-NOS, Nodal T-follicular Helper Cell Lymphoma, and ALK-1 Negative Anaplastic Large Cell Lymphoma. The study aims to address poor survival rates with current CHOP-based therapies in this rare cancer population.

State Public Health Nurse Honored With Nursing Excellence Award for HIV-PrEP Work

The New Mexico Department of Health announced that Gina Fullbright, a registered nurse practitioner with the Public Health Division's Southwest Region, received a Nursing Excellence Award from the New Mexico Center for Nursing Excellence on April 11, 2026. Fullbright was recognized for her work expanding access to HIV-PrEP preventative treatment in southern New Mexico. Four other NMDOH nurses were also nominated for the award.

Wyoming Veterinary Board Disciplinary Actions

The Wyoming Veterinary Medical Board publishes its record of disciplinary actions taken against licensed veterinarians. These actions may include license revocations, suspensions, probations, fines, reprimands, or mandatory continuing education requirements for licensees found in violation of veterinary practice standards.

WV Vet Board Publishes Website Navigation for Licensee Search and Complaint Filing

The WV Veterinary Medical Board published its website navigation structure at wvbvm.org, providing public access to license verification search, complaint filing procedures, practitioner forms, continuing education guidelines, and facility registration information for veterinarians, registered veterinary technicians, and certified animal euthanasia technicians in West Virginia.

Disciplinary Actions, Reprimands, Suspensions, Revocations

The WV Veterinary Medical Board maintains a public webpage listing disciplinary actions taken against veterinarians, registered veterinary technicians, and certified animal euthanasia technicians licensed in West Virginia. Actions include reprimands, suspensions, and revocations. The page provides access to board disciplinary records for public transparency.

Disciplinary Actions and Citations Search Tool

The Utah Division of Professional Licensing (DOPL) provides a public search tool allowing users to query entity names, license numbers, or individual names to discover disciplinary actions and citations issued by the UT Vet Board and other licensing boards. The search is accessible via db.dpl.utah.gov/disciplinary-actions/. This is an informational tool, not a new regulatory requirement or enforcement action.

NCVMB Complaint Process and 3-Year Filing Deadline

The North Carolina Veterinary Medical Board published its complaint filing procedures and statute of limitations. The Board enforces a 3-year deadline from the date of incident for filing complaints against licensees and registrants. Complaints cannot be accepted anonymously, by fax, email, or telephone. The Board investigates incompetence, malpractice, gross negligence, and misrepresentation, with possible outcomes including dismissal, caution, reprimand, or license suspension.

Predictors of Clinical Response After Interlaminar Cervical Epidural Steroid Injection for Cervical Radiculopathy

NIH registered a new observational retrospective cohort study (NCT07535476) on ClinicalTrials.gov to evaluate predictors of clinical response after interlaminar cervical epidural steroid injection in patients with cervical radiculopathy. The study will analyze demographic, clinical, and procedure-related variables including pain scores before and after the procedure. Enrollment is anticipated to begin April 17, 2026.

Complete List of Board Disciplinary Actions

The Wyoming Board of Psychology publishes its complete historical list of disciplinary actions taken against licensed psychologists and applicants. The document provides public access to enforcement records including license revocations, suspensions, probations, fines, and reprimands issued by the board under Wyo. Stat. § 33-27.

Examining Board of Psychology - Board Duties, Members, and 2026 Meeting Schedule

The Washington State Examining Board of Psychology published its annual meeting schedule for 2026 and updated member roster. The board is composed of 9 psychologist members and 2 public members who regulate psychologist competency, licensing, and discipline in Washington. The board meets six times annually and oversees complaint investigations that may result in disciplinary actions from Notice of Correction to license revocation.

ND Joins PSYPACT - Proposed Rules Open for Public Comment

The PSYPACT Commission has published Proposed Rules following North Dakota's joining of the Psychology Interjurisdictional Compact. The proposed rules establish the framework for telepsychology and interjurisdictional psychology practice across member states. The comment period runs for 60 days through October 3, 2023, with a public hearing scheduled for November 16, 2023 at 11:00 am Eastern via Zoom.

PSYPACT Proposes Rules on Residency Definition and Authorization Denial Grounds

The Psychology Interjurisdictional Compact (PSYPACT) Commission has published Proposed Rules open for a 60-day public comment period through October 3, 2025. The proposed rules add a residency definition per PSYPACT Legislation, clarify grounds for denying or revoking authorizations, expand the appeals process to separately address denials and revocations, and revise rule numbering for alignment. Stakeholders may submit written comments via the PSYPACT website.

CE Broker Audit for Psychologist Licensees

The North Dakota State Board of Psychology Examiners announced that continuing education audits for renewing psychologist licensees will now be conducted using CE Broker technology. Licensees selected in the 10% CE audit required by statute must submit their audit information through the CE Broker platform. Licensees are not required to maintain CE records on CE Broker generally, but audit submissions must be made through the platform. Dr. Paul Kolstoe serves as the Board's technical assistant for CE Broker support.

Minnesota Psychology Board Disciplinary and Corrective Actions List

The Minnesota Psychology Board published its updated list of disciplinary and corrective actions against licensed psychologists. The list includes 40 individual orders spanning from September 2023 through March 2026, containing stipulations, consent orders, agreements for corrective action, findings of fact, license suspensions, and unconditional license reinstatements.

How to File Complaints Against Healthcare Professionals and Facilities

The Massachusetts Bureau of Health Professions Licensure (BHPL) issued guidance explaining the complaint filing process against healthcare professionals and facilities. Anyone may submit a complaint via the Online Complaint Portal or paper form. The Bureau may open a formal complaint, pursue staff action investigation, or close the matter. If formal action is taken, outcomes range from advisory letters and non-disciplinary probation to reprimand, suspension, or revocation. The Board requires clear evidence of statutory or regulatory violation to impose sanctions. Investigations may take one month to three years depending on complexity.

Observational Trial NCT07537153 - Unapproved Device

NIH registered observational clinical trial NCT07537153 on ClinicalTrials.gov. The trial involves a device that has not been approved or cleared by the U.S. FDA for its intended use. Registration satisfies FDA requirements for ongoing clinical investigations of unapproved devices. Trial status listed as active with data collection ongoing.

Complaint Form Against Louisiana Psychologists Licensees

The Louisiana State Board of Examiners of Psychologists provides an online complaint form enabling individuals to file complaints against licensed psychologists and specialists in school psychology. The form collects complainant information, details of the person being investigated, and incident descriptions across categories including competence, dual relationships, sexual misconduct, substance abuse, and record release failures. The Board investigates complaints in accordance with LA R.S. 37:2351-2378 and may initiate disciplinary proceedings if warranted.

License Verification Fee $15, Online Search and Mailing List Services

The Louisiana State Board of Examiners of Psychologists (LSBEP) publishes its license verification and search services. License verification costs $15 plus $0.74 online processing fee. A licensee mailing list is available for $100 plus $3.20 processing fee. The board also publishes annual lists of licensed psychologists and specialists in school psychology dating back to 2016.

Kentucky Psychology Board Disciplinary Actions List

The Kentucky Board of Examiners of Psychology maintains a public index of disciplinary actions issued against licensed psychologists from 2000 to present. The list includes recent actions through March 2026 and older actions dating back to 2000, accessible via PDF links for each individual case.

Pre-COSALFA 52 International Seminar on Emergency Vaccination Against Foot-and-Mouth Disease

PANAFTOSA/SPV of PAHO/WHO held the Pre-COSALFA 52 International Seminar on April 14, 2026, in Rio de Janeiro, Brazil, to analyze emergency vaccination against foot-and-mouth disease as a strategic response tool. The seminar addressed progress on the Regional Antigen Bank for Foot-and-Mouth Disease (BANVACO), operational challenges, and gaps in interinstitutional coordination and decision-making. Conclusions will inform the 52nd COSALFA meeting scheduled for April 22–23, 2026, in Georgetown, Guyana.

Team ECC Talks Episode 1 Spotlights Event-Based Surveillance in Eastern Caribbean

PAHO/WHO Office for Barbados and the Eastern Caribbean Countries released Episode 1 of the Team ECC Talks video series, focusing on Event-Based Surveillance (EBS) as an early warning system for public health threats. The episode features PAHO colleagues Dr. Prabhjot Singh and Mrs. Fiona Anthony discussing EBS functions, implementation in small island states, and community engagement strategies. PAHO provides technical assistance, training, and coordination support to ministries of health across the Eastern Caribbean region.

PAHO Supports Barbados Health Minister on Biennial Work Plan 2026–2027

PAHO met with Barbados' newly appointed Minister of Health and Wellness to discuss the Biennial Work Plan 2026–2027. The meeting covered ongoing and planned technical cooperation activities including health systems strengthening, HIV, disease prevention, maternal health, noncommunicable diseases, antimicrobial resistance, and pharmaceutical systems. The engagement sets the foundation for continued collaboration aligning PAHO technical cooperation with Barbados' evolving national health priorities.

Dominica Launches Inaugural Primary Health Care Week Honoring Dr. Carissa Etienne

PAHO/WHO congratulates the Government of Dominica on declaring its inaugural Primary Health Care Week, 13-17 April 2026, honoring Dr. Carissa F. Etienne, Dominican national and Director Emeritus of PAHO. The observance recognizes Dominica's district-based health system serving over 66,000 people through more than 50 public health centres. This is a commendatory statement reaffirming PAHO's support for strengthening community-centered primary health care as the foundation for universal health.

PAHO Launches Policy Briefs on Long-Term Care Across the Americas

PAHO released a new series of policy briefs to support countries in strengthening long-term care systems across the Americas. The documents address person-centered care, caregiver roles, and governance and financing mechanisms. Approximately 14.4% of people aged 65 and older in Latin America and the Caribbean, around 8 million individuals, currently require long-term care, with projections indicating this will rise to 16% by 2050.

Innovations Waiver Providers Must Add 39 Services and Accreditation by April 20

NC Medicaid is updating the Provider Permission Matrix (PPM) for taxonomy 251S00000X to add 39 new Innovations Waiver Service options for Intellectually and Developmentally Disabled (I/DD) service providers. Beginning April 20, 2026, providers must report national accreditation when selecting these services. Providers currently using the single Community/Behavioral Health service must migrate to a new Innovations Waiver Service and report accreditation by April 20, 2027, or lose reimbursement eligibility.

80 New ICD-10-PCS Codes Effective April 1, 2026

CMS has released 80 new ICD-10-PCS procedure codes effective April 1, 2026. NC Medicaid Direct and NC Medicaid Managed Care providers must use these codes for discharges and patient encounters from April 1, 2026 through September 30, 2026. The complete code list is available on the CMS ICD-10 webpage.

Quarterly Provider Update: Provider Directory API Launch, Accreditation Updates, Webinar Schedule

NC Medicaid announces the launch of its Provider Directory API per CMS-9115-F interoperability requirements, making network provider information publicly accessible. Behavioral health providers are reminded of national accreditation requirements per NC Gen Stat § 122C-81. Enrolled providers must disclose adverse actions against licenses, certifications, or accreditations within 30 calendar days under NC Gen Stat 108C-4.

State Directed Payment Programs Approved to Provide $4.5 Billion to Georgia Healthcare Providers

The Georgia Department of Community Health announces approval of State Directed Payment Programs providing $4.5 billion to Georgia healthcare providers. The programs include the $218.8M GREAT Health Program which received federal approval on February 26, 2026. These are state-directed Medicaid payment initiatives targeting rural health transformation and healthcare provider reimbursement.

GA Medicaid Provider Login Portal Navigation

The Georgia Medicaid Provider Portal (mmis.georgia.gov) has posted an alert informing providers that Group Enrollment is now open. Providers can access the Provider Enrollment Application and select the Group/Billing Application Type to enroll groups, entering their existing Payee Medicaid ID on the Payee panel. The deadline to enroll groups has been extended until late spring 2026.

Georgia Gateway Session Timeout and Member Access Portal

Georgia Gateway announces planned system maintenance windows on April 23, 2026 (8:00 PM to 11:00 PM) and April 25, 2026 (6:00 PM to 11:59 PM). The portal provides information for applying to SNAP, TANF, Medicaid, Child Care, and WIC benefits, as well as the Georgia Pathways to Coverage program for eligible adults ages 19-64 with household income up to 100% of the Federal Poverty Level.

Georgia Pathways Healthcare Coverage for Medicaid-Ineligible Residents

Georgia Pathways is a healthcare coverage program administered by the Georgia Department of Community Health for state residents who meet program eligibility requirements but do not qualify for traditional Medicaid. The program offers coverage through the Georgia Gateway eligibility system, with applicants required to complete qualifying activities such as employment, education, or community engagement to maintain eligibility.

Georgia Medicaid Redetermination Dashboard 2023-2024

Georgia Medicaid published a public dashboard tracking redetermination activities and outcomes during the 2023-2024 Medicaid unwinding period. The dashboard provides transparency into renewal processing metrics, enrollment status changes, and case disposition data for Georgia's Medicaid program.

Advisory on Immigration Enforcement Activities in Healthcare and Social Services Facilities

The Pennsylvania Departments of Health, Human Services, Drug and Alcohol Programs, and Aging issued a non-regulatory advisory informing healthcare and social services facilities that the federal DHS has lifted restrictions previously prohibiting immigration enforcement actions at protected locations including hospitals, clinics, shelters, and treatment facilities. The advisory provides information on HIPAA protections for patient health information, distinguishes between judicial and administrative warrants, and recommends that facilities develop written policies and procedures for responding to immigration enforcement agents.

Illinois Child Support Services Celebrates 50th Anniversary, Historic Top-30 Ranking

The Illinois Department of Healthcare and Family Services announced the 50th anniversary of Child Support Services during Child Support Awareness Month. Illinois achieved a historic top-30 national ranking for comprehensive child support services, with a 16th-place ranking for paternity establishment. The Family Resource Connections program was made permanent as part of a whole-family approach. The program serves over 330,000 Illinois families and collects more than $1 billion annually.

Illinois Invests $4M in Planned Parenthood Funding for Reproductive Healthcare

The Illinois Department of Healthcare and Family Services (HFS) announced a $4 million investment in Medicaid family planning programming to backfill federal funding cuts to Planned Parenthood resulting from the Trump Administration's HR1 budget bill. The funding will support contraception, STI testing and treatment, and cancer screenings at Planned Parenthood clinics serving approximately 35,000 Illinois Medicaid customers. Illinois operates 13 Planned Parenthood health centers with an additional clinic in Fairview Heights receiving funding.

Illinois Medicaid Launches Coverage for Home Visiting Services for Pregnant and Parenting Individuals

The Illinois Department of Healthcare and Family Services (HFS) announced new Medicaid coverage for home visiting services for pregnant and parenting individuals, effective November 21, 2025. Covered services include prenatal home visits with health education, blood pressure monitoring, behavioral health screenings, domestic violence education and screenings, stress management, and service referrals. Providers seeking to enroll as home visiting organizations must be certified by the appropriate national governing body. HFS will host a Maternal Child Health Provider Town Hall on December 9 to provide updates and home-visiting training.

Illinois Receives $193M Federal Rural Healthcare Transformation Funding

Illinois has been awarded $193,418,216 per year for five years through the federal Rural Healthcare Transformation Program (RHTP). The Illinois Department of Healthcare and Family Services (HFS) developed the application around three key initiatives: transforming rural healthcare delivery through regional partnerships and value-based care, overcoming geographic barriers through mobile and telehealth services, and building a resilient rural healthcare workforce. Funding will be directed to entities serving the 1.9 million rural residents across 85 Illinois counties.

CMS Releases Fiscal Year 2027 IPPS and LTCH Proposed Rule

CMS released its fiscal year 2027 proposed rule for the Hospital Inpatient Prospective Payment System and Long-Term Care Hospital Prospective Payment System on April 10, 2026. The proposed rule would increase IPPS operating payment rates by 2.4 percent for hospitals meeting quality reporting and EHR requirements, with an estimated $1.9 billion increase in total IPPS payments. Key changes include expansion of the CJR Model into mandatory nationwide CJR-X, refinements to CAR-T therapy reimbursement under MS-DRG 018, and proposals affecting New Technology Add-on Payments. Comments are due June 9, 2026.

Suicide Prevention Training Required for WA Health Professionals

The Washington State Department of Health published an informational page explaining suicide prevention training requirements for healthcare professionals under RCW 43.70.442. Beginning July 1, 2017, affected health professionals must complete training from programs on the state's approved Model List to meet statutory content and time requirements.

License Holders Must Disclose Sexual Misconduct to Patients

Washington State's RCW 18.130.063 requires license holders who have been sanctioned for sexual misconduct on or after October 1, 2019, to disclose this to patients before or at their first appointment. Licensees must provide the public order or stipulation, describe all sanctions and their duration, include the disciplining authority's phone number, and explain how to access more information on the license lookup website. Patients or their surrogate decision makers must sign an acknowledgment of receipt, which must be kept in the patient's file.

COVID-19 Continuing Education Requirements Extension for Naturopathic Physicians

The Washington State Board of Naturopathy adopted policy BON 20-01.1 extending continuing education (CE) requirements for naturopathic physicians during COVID-19. The board exercised authority under WAC 246-12-210 to grant CE extensions due to extenuating circumstances. Naturopathic physicians who attested to CE through September 30, 2020 received coinciding extensions with their license renewals. The board will accept online and prerecorded courses meeting WAC 246-836-080 requirements through December 31, 2021. Case-by-case consideration applies to other circumstances beyond licensees' control.

Oregon Naturopathy Disciplinary Actions 2021-2026

The Oregon Naturopathy Board published a list of 29 disciplinary actions against naturopathic doctors (NDs) spanning 2021 through April 2026. Actions include Final Orders by Default, Consent Orders, Settlement Agreements, and Notices of Proposed Discipline covering case numbers from 2019 through 2024. Cases involve practitioners James Said, Matthew Zorn, Richard Krebs, Lakshmi Andersen, Hyo-Shin Kim, Mary Grabowska, Ryan Wood, Francis Poe, David Geller, Usha Honeyman, Nathalie Paravicini, Leslie Hamlett, Russell Marz, Seth Burrell, Michelle Jackson, Jeri Otterstrom, Sayvi George, Angela Carter, Nesbitt Durr Elmore, Mai Nguyen-Pham, Nathan Daniel McVeigh, Katherine Hofmann, Michael Miller, Jason Black, Jocelyn Cooper, Christina Winkelman, George Gonzales, Mihaela Pepel, and Katherine Walker.

File a Complaint Against Licensee or Unlicensed Activity

The Florida Department of Business and Professional Regulation (DBPR) published an informational page explaining how consumers and other parties may file complaints against licensees or individuals suspected of performing unlicensed activity. The page outlines available disciplinary actions, including reprimand, fine, restriction of practice, remedial education, administrative costs, probation, license suspension, or revocation. The page lists dozens of regulated professions including architecture, cosmetology, construction, engineering, and healthcare professions such as chiropractic medicine.

License Denial or Suspension for Tax Delinquency Under AB 1424

The California Board of Naturopathic Medicine announces statutory requirements under AB 1424 to deny licensure applications and suspend licenses of applicants and licensees appearing on Franchise Tax Board (FTB) or Board of Equalization (BOE) certified lists of top 500 tax delinquencies over $100,000. Affected individuals have 90 days from preliminary notice to satisfy outstanding tax obligations or enter a payment installment program with FTB or BOE. The board cannot refund any fees paid for license issuance or renewal when denied or suspended under this law.

Oxidative Stress in Autoimmune Rheumatic Diseases

NIH National Library of Medicine registered an observational study (NCT07536529) examining oxidative stress markers in autoimmune rheumatic diseases including rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. The study measures blood and tissue redox status to understand free radical impact on biomolecules in inflammatory joint disease patients. This registry entry applies to clinical investigators and healthcare providers involved in the study.

Clinical Decision-Making in FAIS

NIH registered clinical trial NCT07536295 studying dynamic assessment methods for femoroacetabular impingement syndrome (FAIS) surgery decisions. The study aims to develop and validate clinic-ready dynamic assessment methods integrating weight-bearing pelvic alignment with 3D hip modeling to support more objective treatment timing.

Efficacy of Cosmetic Products in Preventing HEVL-Induced Skin Pigmentation

NIH registered a double-blind, randomized clinical trial (NCT07537595) evaluating the efficacy of seven anti-pigmentation cosmetic formulations in preventing skin pigmentation induced by High Energy Visible Light (HEVL, 400-450nm) in 18-60 year old Caucasian healthy volunteers. Participants will undergo 36 visits over 7 weeks with standardized product applications on delineated skin zones followed by HEVL exposure and colorimetric measurements at 13 time points.

Systems and Methods for Automated Ultrasound Image Labeling and Quality Grading

The European Patent Office published patent application EP4028992A1 for Echonous, Inc., titled 'Systems and Methods for Automated Ultrasound Image Labeling and Quality Grading.' The invention covers automated systems using neural networks to label ultrasound images and assess image quality. The patent is designated for all 39 EPC contracting states including DE, FR, GB, IT, ES, NL, and others.

Endoscopic System and Method for Operating the Same (EP4027183A1)

The EPO published patent application EP4027183A1 for Fujifilm Corporation's endoscopic system and method for operating the same. The patent relates to an endoscopic device classified under IPC A61B covering diagnosis and surgery applications. The publication provides intellectual property protection for the disclosed invention across all designated EPC contracting states including AL, AT, BE, DE, FR, GB, IT, NL, and 32 others.

Surgical Robotic Arm with Anatomy State Confirmation, Covidien

The European Patent Office published patent EP4072460A1 for Covidien LP covering a surgical robotic arm system with anatomy state confirmation technology. The invention is classified under IPC A61B (Diagnosis and Surgery) and includes robotic arm mechanisms for confirming anatomical states during surgical procedures. The patent names Meglan Dwight as inventor.

Surgical Stapler with Removable Power Pack, EP3998960A1

European Patent Office published patent EP3998960A1 granting Revmedica, Inc. exclusive rights to a surgical stapler with removable power pack. The patent application was filed by inventors SATTI, WENCHELL, and NIELSEN with IPC classifications covering surgical stapling devices (A61B 17/072, A61B 17/068, A61B 17/115). The patent covers designated European Patent Convention states including DE, FR, GB, IT, ES, NL, and 22 other member states.

Vascular Access Device with Arteriovenous Fistula Support EP4037754A1

The European Patent Office published patent application EP4037754A1 for a vascular access device designed to support arteriovenous fistulas. The patent was filed by Voyager Biomedical, Inc. and inventors Alan Glowczwski and Kimberly Marie Neely. The invention is classified under A61B 17/11 (surgical anastomosis) and A61M 39/02 (vascular implants).

EP4044910A1 Monitoring of Breathing and Heart Function Patent

The European Patent Office published patent application EP4044910A1 titled 'Monitoring of Breathing and Heart Function' filed by The Children's Medical Center Corporation. Inventors Benjamin Matthews and Christopher Norve developed a system for monitoring breathing and heart function with applications in medical diagnostics. The patent application was published with designated state coverage across European Patent Convention member states including Germany, France, United Kingdom, Italy, Spain, and 23 other countries.

Intra-Oral Electroencephalography Device and Method for Neurological Diagnosis

The European Patent Office granted Patent EP4054420A1 to Achaemenid, LLC for an intra-oral electroencephalography (EEG) device designed for neurological diagnosis. The invention (Inventor: Reza Radmand) utilizes IPC classifications including A61B 5/291 (electrical recording of physiological state), A61B 5/384 (brain monitoring), and A61B 5/11 (movement measurement). The patent is designated for all 35 participating EPC contracting states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states.

Systems for Assessing Gait, Stability, and/or Balance of a User

European Patent Office granted patent EP4048148A1 to Plethy, Inc. covering AI systems for assessing gait, stability, and balance using neural networks. The patent application was published April 8, 2026, designating multiple European member states including DE, FR, GB, IT, NL, ES, and others.

Brain Control Interface Patent - Synchron Australia

The European Patent Office published patent application EP4048371A1 for Synchron Australia Pty Ltd, covering systems and methods for configuring a brain control interface using data from deployed systems. The patent application includes claims related to A61N 1/05 (neural electrodes), A61N 1/36 (nerve stimulation), and related classifications. The application designates multiple European member states including DE, FR, GB, IT, NL, and others.

California DCC Reminds Consumers to Use Licensed Retailers

The California Department of Cannabis Control (DCC) issued a consumer safety reminder ahead of the 4/20 cannabis holiday, urging consumers to purchase cannabis only from licensed retailers. The DCC states that licensed retailers offer products that are tested, accurately labeled, and tracked through the state's regulatory system.

European Patent - Clinical Event Evaluation - Edwards Lifesciences

The European Patent Office published European patent application EP4505472A1 for Edwards Lifesciences Corporation covering systems and methods for clinical event evaluation in health informatics. The patent includes IPC classifications G16H 10/20, G16H 50/70, G06F 40/20, G16H 15/00, and G16H 50/20, with designated states across EU member states and other European countries.

Wearoptimo Measurement Analysis Patent EP4482372A1

The European Patent Office granted patent EP4482372A1 to Wearoptimo Pty Ltd covering measurement analysis technology. The patent includes claims related to A61B 5/00 (measuring for diagnostic purposes), G16H 50/30 (ICT for treatments or procedures), and G06N 20/00 (machine learning). The patent is designated for all EPC contracting states including DE, FR, GB, IT, NL, and 24 other jurisdictions.

Device, System, and Method for Determining and Increasing Clinician Engagement with Infusion Devices

The European Patent Office published European Patent Application EP4721093A1 for CareFusion 303, Inc., titled 'Device, System, and Method for Determining and Increasing Clinician Engagement with Infusion Devices.' The patent application was published April 8, 2026, with inventors including Daniel M. Abal, covering G16H 40/40 and G16H 40/63 classifications related to healthcare informatics and medical device management systems. The patent is valid in designated European states including AT, BE, DE, ES, FI, FR, GB, IT, NL, and others.

Systems and Methods for Predicting Patient Recruitment at Clinical Sites

EPO published patent application EP4394784A1 by Tempus AI, Inc. titled 'Systems and Methods for Predicting Patient Recruitment at Clinical Sites.' The invention relates to health informatics systems using predictive algorithms for clinical trial site patient recruitment. The application covers G16H classifications in health informatics. The designated states include all EPO member states covering major European markets.

Calibrating a Digital Image of Skin Tissue

The European Patent Office published patent application EP4531674A1 for a method of calibrating digital images of skin tissue. The application was filed by AI Labs Group, S.L. and lists Taig Mac Carthy Espinar and Alfonso Medela Ayarzaguena as inventors. The patent covers calibration techniques for digital skin tissue imaging using IPC classifications including A61B 5/103 and G16H 50/20.

METHOD FOR PATIENT POSITIONING IN A MEDICAL PROCEDURE AND MEDICAL SYSTEM

The European Patent Office granted patent EP4553843A1 to Koninklijke Philips N.V. on April 8, 2026. The patent covers a method and system for patient positioning in medical procedures, utilizing graphics and visualization technologies. The patent is designated across all EU member states and extended European countries.

Systems and Methods for Monitoring Efficacy of Cytotoxic Treatment

The European Patent Office published patent application EP4500551A1 for Washington University, covering systems and methods for monitoring the efficacy of cytotoxic treatments. The patent application includes IPC classifications related to health informatics (G16H), pharmaceutical compositions (A61K), and genetic testing methods (C12Q). The designated contracting states include all major European Economic Area countries, granting Washington University exclusive intellectual property rights in Europe upon grant.

Imaging System for Calculating Fluid Dynamics, EP4463053A1

The European Patent Office published patent EP4463053A1, titled 'Imaging System for Calculating Fluid Dynamics', granted to Gentuity, LLC. The patent covers imaging system technology for fluid dynamics calculation and is classified under health informatics (G16H). The patent designation extends across EU member states including Germany, France, and the United Kingdom.

Probability of Medical Condition

The European Patent Office published patent application EP4553849A1 filed by Koninklijke Philips N.V. The invention covers systems and methods for assessing the probability of medical conditions using medical image processing and machine learning algorithms. The application is classified under IPC G16H (Health Informatics) and is now publicly available.

Penn State Research Foundation Multi-Destination Endoscopic Surgery Planning System Patent EP4468937A1

The European Patent Office published patent application EP4468937A1 filed by The Penn State Research Foundation for a multi-destination procedure planning and guidance system for endoscopic surgery. The application covers IPC classifications G16H 20/40, G16H 50/50, A61B 1/00, A61B 34/00, A61B 34/10, A61B 34/20, A61B 1/267, and A61B 90/00. The patent is designated for all 38 European Patent Convention contracting states including Germany, France, Italy, Spain, and the United Kingdom.

Lentiviral Vectors Patent - Oxford BioMedica (UK) Limited EP4118217A1

The European Patent Office published patent application EP4118217A1 for Oxford BioMedica (UK) Limited covering lentiviral vectors (IPC C12N 15/86). Jordan Wright is listed as the inventor. The patent designates all listed European member states including DE, FR, GB, IT, ES, NL, BE, CH, and others. Patent grants provide exclusive commercial rights to the holder.

Bisdemethoxycurcumin Compositions for Managing Chronic Obstructive Pulmonary Disease (EP4090340A1)

The European Patent Office published patent application EP4090340A1, filed by Sami-Sabinsa Group Limited, covering compositions comprising bisdemethoxycurcumin for managing chronic obstructive pulmonary disease (COPD). The patent names Muhammed Majeed, Kalyanam Nagabhushanam, Sarang Bani, and Anjali Pandey as inventors. The application is classified under A61K 31/12 (ketone-based therapeutic compositions) with designations across 37 European contracting states including all EU member states.

Hydrogels Cultured Meat Production Patent EP4100445A1

The European Patent Office granted Patent EP4100445A1 to Mosa Meat B.V. for hydrogels used in cultured meat production. The invention covers biomaterial compositions (C08B 37/00, C08L 5/04) and methods for culturing animal cells (C12N 5/00, C12N 5/077). The patent is valid in 31 designated contracting states including major markets across the EU, UK, Switzerland, Norway, and Turkey.

Soluble ENPP1 or ENPP3 Proteins and Uses Thereof

The European Patent Office published application EP4162036A1 for BioMarin Pharmaceutical Inc. and Yale University covering soluble ENPP1 or ENPP3 proteins and their uses. The patent application was published April 8, 2026 with A1 designation (first publication with European search report). The application designates all European contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Anti-TIGIT Antibodies and Usage Method

The European Patent Office published patent application EP4089115A1 titled 'Anti-TIGIT Antibodies and Usage Method' filed by Shanghai Henlius Biotech, Inc. The patent covers anti-TIGIT antibodies and their usage methods, classified under C07K 16/28 with applications in cancer treatment (A61P 35/00). The application designates 34 European member states including DE, FR, GB, IT, ES, NL, and CH.

Boosting Homology Directed Repair in Plants (EP4172340A1)

The EPO has granted patent EP4172340A1 to KWS SAAT SE & Co. KGaA for methods of boosting homology directed repair in plants. The patent application (C12N 15/82) was published on April 8, 2026, with inventor Yu Mei. This establishes intellectual property rights in designated European states for agricultural biotechnology applications.

EP4139921A1 - Method and System for Identifying Candidate Immunogenic Protein Regions for Vaccine Development

The European Patent Office published application EP4139921A1 for NEC OncoImmunity AS, covering a computational method and system for identifying candidate regions of source proteins predicted to instigate an immunogenic response. The invention has applications in vaccine development and creates enforceable patent rights across 36 designated European member states.

PCSK9 Antagonist Patent Application by Argonaute RNA Limited

The European Patent Office published application EP4081642A1 for Argonaute RNA Limited, covering RNA-based antagonists of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9). Inventors are Daniel Mitchell and Michael Khan. The patent is classified under IPC C12N 15/113 and designates all contracting states of the European Patent Convention.

EP4127152A1 - Methods for Identifying Genomic DNA Bound to Protein

EPO published patent application EP4127152A1 for Altius Institute for Biomedical Sciences and The Brigham & Women's Hospital, Inc. The invention covers methods, compositions, and kits for identifying regions of genomic DNA bound to a protein. The application was published under the A1 publication kind code on April 8, 2026.

Pancreatic Cancer Detection Kit - Toray Industries

The European Patent Office published application EP3988668A2 for a kit and method detecting early-stage pancreatic cancer and precursor lesions. Applicants are Toray Industries, Inc. and the National Cancer Center. The application covers all EPC contracting states (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR). The technology uses genetic detection methods classified under C12Q 1/68.

PIP Framework Marks 15 Years of Global Health Equity

The WHO published a commemorative message marking the 15th anniversary of the Pandemic Influenza Preparedness (PIP) Framework, adopted by the World Health Assembly in May 2011. The PIP Framework is described as the world's first functioning global access and benefit-sharing system for public health, promoting timely sharing of pandemic-potential influenza viruses and equitable distribution of resulting vaccines, antivirals, and diagnostics. Over 15 years, the Partnership Contribution has supported capacity strengthening in 86 countries across all six WHO regions, spanning laboratory and surveillance, regulatory functions, risk communications, community engagement, pandemic planning, and disease burden assessment.

Draft Compliance Policy for NIOSH-Approved Respirators Under 21 CFR 878.4040 and 880.6260

FDA's Center for Devices and Radiological Health (CDRH) has issued draft guidance establishing a proposed compliance policy for respirators approved by CDC NIOSH under 42 CFR part 84. The draft applies to surgical N95 respirators and other NIOSH-approved air-purifying respirators, including PAPRs, non-powered FFRs, elastomeric respirators, and FFRs for general public use in public health emergencies. FDA seeks public comments on the compliance policy by June 19, 2026.

Expanded Access to Investigational Drugs for Treatment Use: Questions and Answers

FDA's Center for Drug Evaluation and Research issued guidance (Docket FDA-2013-D-0446) clarifying expanded access regulations for investigational drugs under 21 CFR part 312, subpart I, addressing frequently asked questions from industry, researchers, physicians, institutional review boards, and patients. The guidance incorporates statutory requirements from the 21st Century Cures Act and FDA Reauthorization Act of 2017. The document is available for ongoing public comment through the regulations.gov docket system.

EBV Reactivation Longitudinal Cohort Study, 100 Adults, 18-29, Australia

NIH registered observational cohort study NCT07536048 on ClinicalTrials.gov tracking EBV reactivation in 100 EBV seropositive adults aged 18-29 years in Australia. The prospective longitudinal study will follow participants over 6-12 months with no study interventions. Participants will undergo immunological and clinical data collection at designated study centers.

Group Music Therapy Pilot, Emotional Health, Long-Term Care

This is a ClinicalTrials.gov registration for a pilot study (NCT07536360) evaluating group music therapy's effects on emotional health among long-term care residents. The study will also assess the feasibility of using AI-based facial emotion recognition technology (PaLI Gemma 2 multimodal model) alongside traditional self-reported emotional health questionnaires. Participants will attend six 60-minute weekly sessions with pre/post assessments.

Correlation Between Smartphone Addiction, Sleep Problems and Body Mass Index in School Age Children

NIH registered an observational study (NCT07536334) on ClinicalTrials.gov examining the relationship between smartphone addiction, sleep problems, and BMI in school-age children. The study is an observational cohort with no interventions. Conditions include obesity, overweight, and sleep disorders. No compliance obligations are created by this study registration.

Impact of PDT and Topical Corticosteroids on Taste Perception in Patients With OLP

NIH ClinicalTrials.gov registered a new comparative effectiveness study (NCT07536737) evaluating photodynamic therapy versus topical corticosteroids for treating oral lichen planus and their effects on taste perception. The randomized controlled trial will enroll patients receiving either 5-Amino Levulinic Acid-based PDT or Clobetasol Propionate 0.05% Cream, assessing taste recognition and lesion outcomes. Study findings may inform clinical treatment selection for OLP patients experiencing taste disturbances.

Nurse-Led Nutrition and Exercise Program for Hemodialysis Patients

NIH registered a randomized controlled trial (NCT07535957) evaluating a nurse-led integrated nutrition and exercise intervention for hemodialysis patients. The study will compare structured nutritional counseling and supervised exercise against usual care, measuring quality of life improvements over a follow-up period.

Aloe Vera-Peppermint Gel Pressure Injury Prevention ICU Randomized Controlled Trial

NIH ClinicalTrials.gov registered a randomized controlled trial (NCT07537101) evaluating whether combined Aloe Vera-Peppermint gel application reduces pressure injury incidence compared to standard hospital nursing care among ICU patients. Participants will be randomly assigned to receive either the gel intervention or standard care. The trial targets adult ICU patients at risk for pressure injuries (bedsores).

Predictors & Mechanisms of Adolescent PTSD - Early Phase 1 Clinical Trial NCT07537764

The NIH registered Early Phase 1 clinical trial NCT07537764 on ClinicalTrials.gov to study biobehavioral predictors and mechanisms of PTSD response in trauma-exposed adolescents. The study will assess brain activity, physiological responses, and behavior during experimental tasks involving threat reactivity, emotion regulation, and script-driven imagery. Findings may inform future exposure-based intervention development for adolescent PTSD.

Method for Preparing Polydopamine Nanomotor Using Urease and Use of Same

USPTO granted Patent US12599571B2 to POSTECH Research and Business Development Foundation for a biocompatible polydopamine nanomotor using urease. The nanomotor is designed to infiltrate bladder walls in biological environments and remain inside the bladder for extended periods. The patent includes 10 claims covering the preparation method and therapeutic applications.

Shapiro Administration's Work to Combat STIs Leads to Dramatic Decrease in Reportable Diseases

The Pennsylvania Department of Health announced a 28% decrease in congenital syphilis cases from 2024 to 2025, with 90% of syphilis patients receiving treatment within 14 days. Secretary of Health Dr. Debra Bogen highlighted free STI testing, treatment, and counseling available at all 59 State Health Centers during STI Awareness Week.

National Survey of Health Information Exchange Organizations (HIO) - 60-Day Comment Request

HHS ONC is requesting public comment on a revised information collection for the National Survey of Health Information Exchange Organizations (HIO). The survey (OMB No. 0955-0019) collects data on HIO capabilities including technical standards adoption, information blocking perceptions, TEFCA connectivity, public health data exchange, and organizational demographics. This 3-year approval request revises a survey previously approved in 2022 and 2024, removing low-relevance questions and updating wording to align with current policy priorities. Comments are due June 22, 2026.

CMS-10950 Acute Hospital Care at Home Waiver Information Collection Request

CMS published a Paperwork Reduction Act notice announcing an opportunity for public comment on a new information collection request (OMB Control No. 0938-1384) related to the Acute Hospital Care at Home (AHCAH) waiver program. The collection covers submission requirements for hospitals seeking AHCAH waivers that allow at-home acute hospital-level care. To date, 433 hospitals have submitted waiver requests with 396 approved. Comments are due June 22, 2026.

Agency Information Collection Activities: Submission for OMB Review; Comment Request

CMS published a notice announcing two information collection requests under the Paperwork Reduction Act: (1) an extension of CMS-10242 covering Emergency Ambulance Transports and Beneficiary Signature requirements (affecting 10,278 respondents, 9,265,931 annual responses), and (2) a reinstatement of CMS-1771 covering Emergency and Foreign Hospital Services claims under 42 CFR 424.103. The notice invites public comment on burden estimates and information collection aspects. Comments must be received by the OMB desk officer by May 20, 2026.

Intradermal Acupuncture Ocular Surface Facial Paralysis

The NIH has registered a clinical trial (NCT07537426) examining the efficacy of intradermal acupuncture for treating ocular surface diseases following intractable facial paralysis. The randomized controlled trial will compare active acupuncture intervention against sham-needle placebo, with the primary endpoint measured by Ocular Surface Disease Index score reduction.

Observational Study: Respiration Measured Via End-Tidal CO2 and Spirometry

NIH's ClinicalTrials.gov registered an observational study (NCT07537478) titled RESPI to collect respiration data via end-tidal CO2 and spirometry and compare the two measurement methods. The study focuses on respiration rate detection conditions using wearable respiration masks as interventions. This is a registry entry for an observational clinical study with no immediate compliance obligations.

Effectiveness of Autobrush® Versus Manual Toothbrush Among Adolescents With Fixed Orthodontic Appliances

NIH ClinicalTrials.gov registered a randomized crossover clinical trial (NCT07537790) comparing the effectiveness of Autobrush® U-shaped automatic toothbrush versus conventional manual toothbrush in reducing dental plaque among adolescents aged 12-15 with fixed orthodontic appliances. The study will measure Full Mouth Plaque Score (FMPS) as the primary outcome and is being conducted at KAUD in Saudi Arabia.

Vonoprazan vs Esomeprazole H. pylori Eradication Phase 4 Study

NIH registered a Phase 4 clinical trial (NCT07537634) comparing vonoprazan-based levofloxacin-containing triple therapy versus esomeprazole-based levofloxacin-containing triple therapy for Helicobacter pylori eradication in adults with dyspepsia. The randomized open-label study will randomly assign participants to 14-day treatment regimens with follow-up stool antigen testing at 4 weeks post-therapy to assess eradication efficacy and adverse effects.

Inulin-Spirulina Co-intervention for Insomnia Disorder

NIH National Library of Medicine registered a clinical trial (NCT07537192) on ClinicalTrials.gov investigating inulin and spirulina dietary supplements as co-interventions for insomnia disorder in adults aged 18 to 60 years. The 12-week randomized controlled trial will enroll participants in four arms (inulin, spirulina, combined, placebo) and measure sleep quality, mood, anxiety, and cognitive outcomes. Researchers will monitor adverse events and collect polysomnography and biospecimen data at baseline and week 12.

Characterization of JAK1 and JAK2 Activation in Gingival Tissues During Homeostasis and Periodontitis

The NIH registered ClinicalTrials.gov study NCT07536204, an observational study examining JAK1/2 pathway activation in gingival tissues from adults with healthy gingiva and those with periodontitis. The study aims to determine whether the JAK1/2 pathway is overactivated in periodontitis compared to health. Participants will donate gingival tissue for analysis.

Testing Non-Nutrition Menu Labels on Food Selections

NIH registered clinical trial NCT07536126 testing the effects of environmental harm menu label designs on the healthfulness of fast-food meal choices. The randomized study will have participants complete hypothetical online meal ordering tasks across five labeling conditions to assess impacts on healthfulness, nutrient content, and price. Secondary outcomes include label noticeability and consumer perceptions across conditions.

Phase 1 Aclarubicin CAOP Trial for Cutaneous T-Cell Lymphoma

NIH registered Phase 1 trial NCT07535710 on ClinicalTrials.gov evaluating Aclarubicin combined with Cyclophosphamide, Vincristine, and Prednisone (CAOP) in patients with previously treated Cutaneous T-cell Lymphoma. The study aims to determine maximum tolerated dose, safety, and efficacy of the regimen. Aclarubicin is an anthracycline antibiotic notable for lacking cardiotoxicity compared to traditional anthracyclines like doxorubicin.

Xeomin and Tadalafil Phase 2 ED Trial

NIH registered a Phase 2 clinical trial (NCT07537855) evaluating intracavernosal incobotulinumtoxinA (Xeomin, 100 Units) combined with tadalafil for treating mild-moderate erectile dysfunction in approximately 30 million affected men. The randomized crossover pilot study enrolls male participants to assess efficacy where PDE5 inhibitors alone may be insufficient. ClinicalTrials.gov study record posted April 17, 2026.

Center for Scientific Review Notice of Closed Meetings

The NIH Center for Scientific Review published a Federal Register notice announcing seven closed meetings scheduled between May 19 and June 9, 2026. The meetings involve Special Emphasis Panels and Integrated Review Groups reviewing grant applications and contract proposals for research including diabetes, infectious diseases, neurology, cancer, and clinical studies. Meetings are closed pursuant to the Government in the Sunshine Act to protect confidential trade secrets, commercial property, and personal information of grant applicants. The notice satisfies the Federal Advisory Committee Act requirement for advance notice of closed advisory committee meetings.

NIH Clinical Center Research Hospital Board Meeting Notice

The NIH Office Director announces a hybrid meeting of the NIH Clinical Center Research Hospital Board on June 12, 2026, from 9:00 a.m. to 1:00 p.m. The meeting will be held at NIH Building 31, Conference Room 6C02 A & B, Bethesda, MD, and virtually via NIH Videocast. The agenda includes NIH and Clinical Center Leadership Announcements, an update from the CC Acting CEO on recent activities and organizational priorities, and other board business. The meeting is open to the public.

Center for Scientific Review Notice of 11 Closed Meetings

The National Institutes of Health published a notice announcing 11 closed meetings of the Center for Scientific Review in May 2026. The meetings will review and evaluate grant applications across various research areas including biomedical informatics, blood-brain barrier studies, bacterial virulence, and clinical trials. Meetings are closed to the public under the Federal Advisory Committee Act provisions.

Notice of Diabetes Mellitus Interagency Coordinating Committee Meeting

The NIH announces a meeting of the Diabetes Mellitus Interagency Coordinating Committee (DMICC) on June 24, 2026, from 12:00 to 3:00 p.m. EDT. The virtual meeting will focus on 'Innovative Research Partnerships in Diabetic Retinal Disease: Insights and Opportunities' and is open to the public. Individuals interested in presenting oral comments must notify the contact person at least 5 days in advance.

National Institute of Neurological Disorders and Stroke Council Meeting Notice

The NIH National Institute of Neurological Disorders and Stroke has announced a public meeting of the National Advisory Neurological Disorders and Stroke Council on May 20, 2026, from 10:00 a.m. to 5:00 p.m. The virtual meeting will include reports from the Acting Director, program updates on HEAL and Small Business programs, and an overview of intramural activities. Interested persons may submit written comments to the Contact Person at least 10 days in advance of the meeting.

National Institute of Dental and Craniofacial Research Advisory Council Meeting Notice

NIH's National Institute of Dental and Craniofacial Research announces a meeting of the National Advisory Dental and Craniofacial Research Council on May 19-20, 2026, in Bethesda, MD and virtual format. The closed session on May 19 will review grant applications; the open session on May 20 will include the Director's report and concept clearances. A backup meeting is scheduled for July 9, 2026.

NIEHS Partially Closed Meeting Notice - National Advisory Environmental Health Sciences Council

NIEHS published notice of a partially closed meeting of the National Advisory Environmental Health Sciences Council on June 24, 2026. The meeting includes open sessions on microplastics research, environmental health sciences programs, and health/weather research coordination. A closed session from 4:00-6:00 p.m. will review grant applications under FOIA exemption provisions. Interested persons may submit written comments or request to present oral comments to the committee.

NCATS Advisory Council Meeting Notice May 21-22

The NIH National Center for Advancing Translational Sciences (NCATS) has published notice of its Advisory Council meeting scheduled for May 21-22, 2026. The closed session on May 21 will review grant applications, while the open session on May 22 will cover the Center Director's report, program updates, and concept clearances. The meeting will be held at NCI Shady Grove in Rockville, MD, with virtual access available.

Potential New Indication for Testosterone Replacement Therapy

FDA announced it has reviewed published literature suggesting testosterone replacement therapy (TRT) may be safe and effective for treating low libido in men with decreased libido associated with idiopathic hypogonadism. The Agency encourages holders of approved TRT new drug applications to contact FDA by April 30, 2026, for information on submitting a supplemental NDA for this potential new indication.

Establishing Impurity Specifications for Antibiotics Draft Guidance

FDA announced availability of draft guidance titled 'Establishing Impurity Specifications for Antibiotics,' providing recommendations for establishing specifications for organic impurities in antibiotics manufactured by fermentation and semi-synthesis. The draft guidance applies to antibiotic drugs subject to approval under NDAs, ANDAs, and associated type II drug substance DMFs, as well as OTC monograph antibiotic drugs. Comments are due by June 22, 2026.

Compliance Policy Regarding Premarket and Other Requirements for Certain NIOSH Approved Air-Purifying Respirators

FDA announced draft guidance providing a proposed compliance policy for respirators approved by CDC NIOSH under 42 CFR part 84, including surgical N95 respirators, PAPRs, reusable elastomeric respirators, and FFRs for general public use during public health emergencies. Once finalized, the guidance is intended to facilitate more efficient and effective use of resources consistent with least burdensome device policies.

Sintilimab Plus Lenvatinib Phase 3 Trial for Oligo-Extrahepatic Metastatic Hepatocellular Carcinoma

The NIH ClinicalTrials.gov registry published a Phase 3 study (NCT07537946) evaluating sintilimab plus lenvatinib with or without consolidative therapy in patients with oligo-extrahepatic metastatic hepatocellular carcinoma. The randomized 1:1 trial enrolls participants who achieved disease control after 4 induction cycles. The primary endpoint is overall survival.

GEN-AL-RF Trial: Genicular Nerve RF Ablation vs Alcohol Neurolysis for Knee Osteoarthritis Pain

The NIH ClinicalTrials.gov registry has published NCT07537335, a randomized controlled trial comparing genicular nerve radiofrequency ablation to neurolytic alcohol injection for managing chronic knee pain in osteoarthritis patients. The 6-month study will assess pain intensity using the Numeric Rating Scale, physical function via WOMAC scores, and quality of life through SF-12 metrics. Results aim to provide comparative effectiveness evidence for these interventional pain management techniques.

Clinical Trial Evaluating Moxibustion for Cold-Syndrome Allergic Rhinitis

NIH's ClinicalTrials.gov has registered a new interventional study (NCT07537439) evaluating the adjunctive effects of mild moxibustion combined with fluticasone propionate (100 mcg) for treating cold-syndrome allergic rhinitis. The randomized trial will assess outcomes including symptom relief, quality of life, and work productivity in patients with IgE-mediated allergic rhinitis. Estimated study completion date is April 17, 2026.

Effects of Music During Walking on Pain and Muscle Activation in People With Chronic Pain Due to Knee Osteoarthritis

NIH registered a new clinical trial on ClinicalTrials.gov (NCT07537114) to study the effects of rhythmic auditory stimulation—walking with music versus walking with a metronome versus walking without sound—on pain and muscle activation in individuals with chronic knee osteoarthritis. The trial will enroll participants receiving one of three interventions: rhythmic auditory stimulation with music, rhythmic auditory stimulation with a metronome, or a control group with no auditory cueing.

SEHAT Virtual Oral Health Promotion for School Adolescents in Pakistan

NIH registered clinical trial NCT07536958 on ClinicalTrials.gov, a cluster-randomized trial evaluating the SEHAT virtual oral health promotion program among school adolescents in Pakistan. The trial will compare virtual SEHAT sessions delivered via Zoom against conventional in-person oral health education and a control group, assessing outcomes including toothbrushing behavior, plaque scores, gingival scores, and oral health knowledge.

Benmelstobart Plus Anlotinib Combined With SBRT for Hepatocellular Carcinoma

NIH ClinicalTrials.gov registered Phase 2 trial NCT07537777 evaluating Benmelstobart plus anlotinib combined with stereotactic body radiation therapy (SBRT) in patients with oligometastatic hepatocellular carcinoma who have failed first-line targeted therapy. The prospective, single-arm, multicenter study will assess progression-free survival, objective response rate, disease control rate, overall survival, and treatment safety. Eligible patients receive anlotinib 10mg on days 1-14 every 3 weeks plus Benmelstobart 1200mg on day 1 every 3 weeks combined with SBRT.

Phase I Study: Itraconazole Effect on Pharmacokinetics of HS-10506

The NIH ClinicalTrials.gov registry has registered Phase I clinical trial NCT07535970, a single-center, open-label, fixed-sequence, self-controlled study evaluating the effect of itraconazole (a CYP3A inhibitor) on the pharmacokinetics of HS-10506 tablets in healthy Chinese adult participants. The trial is categorized as Phase 1 and is expected to begin on April 17, 2026.

Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases

NIH ClinicalTrials.gov has registered NCT07537959, a randomized trial evaluating whether adding primary tumor resection to standard immune-based systemic therapy improves survival in hepatocellular carcinoma patients with extrahepatic metastases. The study will enroll approximately 252 participants and measure overall survival as the primary endpoint.

EENC Clinical Trial: 162 Mother-Baby Pairs, Shaikh Zayed Hospital, Pakistan

NIH ClinicalTrials.gov registered study NCT07535684 examining Early Essential Newborn Care (EENC) versus routine postnatal care. The single-center trial enrolled 162 mother-baby pairs at Shaikh Zayed Hospital, Rahim Yar Khan, Pakistan. EENC interventions include immediate drying, skin-to-skin contact, delayed cord clamping, thermal care, and breastfeeding initiation within one hour. The study assesses newborn outcomes including early breastfeeding, exclusive breastfeeding at 7 days, hypothermia, hypoglycemia, NICU admission, and maternal outcomes.

Arius Recordings LLC Variance Application

FDA's Center for Devices and Radiological Health (CDRH) received a variance application from Arius Recordings LLC. The application seeks relief or exemption from specific FDA regulatory requirements under 21 CFR. No documents are currently available for public viewing, and the application remains under agency review.

FDA Complaint FDA-2026-H-3613 Closed - No Documents Available

The FDA posted a complaint record (FDA-2026-H-3613) on April 17, 2025. The complaint was filed by the Center for Tobacco Products (CTP) and has been closed. No documents are available for public review or download. This is a procedural record indicating closure of an unspecified complaint matter.

FDA Center for Tobacco Products Files Complaint FDA-2026-H-3876

The FDA Center for Tobacco Products (CTP) filed a formal complaint (FDA-2026-H-3876-0001) on April 16, 2026. The complaint document is available as an attachment on Regulations.gov. No additional details about the specific allegations, parties involved, or requested relief are accessible in the available metadata.

Variance Approval to VarsIQ Media

The FDA Center for Devices and Radiological Health (CDRH) has issued a variance approval letter to VarsIQ Media. Variances are exemptions or waivers from specific regulatory requirements under the Federal Food, Drug, and Cosmetic Act. This approval modifies the applicable regulatory requirements for VarsIQ Media, allowing deviation from certain standard CDRH requirements.

FDA Denies Citizen Petition FDA-2025-P-3263 from George W. Murgatroyd III

FDA CDER issued a final response letter denying citizen petition FDA-2025-P-3263 submitted by George W. Murgatroyd III. The petition was denied by the Center for Drug Evaluation and Research. No additional details are available as the document attachments contain personally identifiable information and are not publicly accessible.

FDA DMB Acknowledgment Letter to VIP Lighting NWA

FDA's Center for Devices and Radiological Health (CDRH) issued an acknowledgment letter to VIP Lighting NWA regarding submission FDA-2026-V-3710. The document serves as administrative confirmation of receipt of a filing, though the specific submission details are not publicly viewable in the available record. No regulatory obligations, deadlines, or penalties are stated in the acknowledgment.

Animal Generic Drug User Fee Act Reauthorization; Public Meeting and Comment Request

FDA announces a virtual public meeting on May 27, 2026 regarding the Animal Generic Drug User Fee Act (AGDUFA) reauthorization and requests public comments through December 1, 2027. The AGDUFA program, which funds FDA's review of generic animal drug submissions, expires September 30, 2028 without new legislation. FDA is soliciting input on program performance and suggestions for the next authorization.

FDA CTP Complaint Filed and Closed

FDA's Center for Tobacco Products (CTP) filed a complaint on April 16, 2026, which has since been closed. The document record indicates only that a complaint was filed and subsequently closed, with the full complaint content not available in the regulatory docket. No additional details regarding the nature of the complaint, parties involved, or any resulting enforcement actions are provided in the available metadata.

Qualitative Data Research Clearance Extension, OMB Control No. 0910-0891

The FDA published a notice under the Paperwork Reduction Act announcing an opportunity for public comment on extending OMB Control Number 0910-0891, the Generic Clearance for Qualitative Data to Support Social and Behavioral Research. The clearance covers submissions for qualitative data to support research related to food, dietary supplements, cosmetics, and animal food and feed. Comments must be submitted by June 16, 2026.

VarsIQ Media Ohio Variance Application - CDRH

FDA's Center for Devices and Radiological Health (CDRH) received a variance application from VarsIQ Media seeking relief from specific FDA regulatory requirements. The application was filed under docket FDA-2026-V-3708-0001 in Ohio. No supporting documents are currently available for review on the regulatory portal. This filing represents a request for FDA to exercise regulatory flexibility under applicable medical device regulations.

Methods and Systems for Determining Optimal Decision Time Related to Embryonic Implantation

USPTO granted patent US12591781B2 to Fairtility Ltd. covering AI and machine learning methods and systems for analyzing time-lapse images of developing embryos to predict embryo viability and determine optimal timing for in-vitro fertilization embryo transfer/implantation. The patent covers morpho-kinetic signature analysis from fertilization through blastulation stages. The patent includes 26 claims and is classified under CPC codes in the G16H health informatics range.

Redirect Health Patent Integrates Healthcare Data Using AI

USPTO granted Patent US12591937B1 to Redirect Health, Inc. on March 31, 2026. The patent covers systems for integrating healthcare data from multiple sources using AI networks to generate predictive outputs. The system incorporates multifaceted authorization to access data from various databases and integrate them into a single data warehouse for predictive analysis.

Post-Discharge Monitoring Threshold Mechanism Patent

USPTO granted Patent US12592142B2 to Koninklijke Philips N.V. covering a mechanism for setting time-dependent thresholds for post-discharge monitoring of target subjects. The patent includes 20 claims and was filed on July 19, 2022.

AI Medical Care Coordination Patent, 24 Claims

The USPTO granted patent US12592299B2 to Care Coordination Systems, LLC on March 31, 2026, covering an AI system for coordinating medical care with 24 claims. The patent describes a system including a hub computing device, data collection for patient and provider information, a graphical user interface for real-time gap analysis, and a neural network providing predictive suggestions. Patent grants establish enforceable intellectual property rights.

Rural Health Network Development Planning Program Performance Measures OMB Revision

HRSA submitted an Information Collection Request to OMB for review and approval under the Paperwork Reduction Act of 1995. The agency seeks public comments by May 20, 2026, on revised performance measures for the Rural Health Network Development Planning Program. The proposed revision reduces the total number of measures from 24 to 15, consolidating sections into 'Capacity/Organizational Information' and 'Sustainability.' Estimated annual burden is 281.25 hours across 25 respondents at 11.25 hours per response.

Intra-Arterial Tirofiban After Complete Recanalization for Acute Intracranial Large-Vessel Occlusion

NIH registered a Phase 3 clinical trial (NCT07537933) to evaluate whether immediate intra-arterial tirofiban after complete recanalization improves recovery in adults with acute ischemic stroke caused by anterior circulation large-vessel occlusion. The trial will enroll approximately 520 participants and compare tirofiban treatment with no tirofiban, measuring good functional outcome at 90 days and symptomatic intracranial hemorrhage risk. Primary completion is expected April 17, 2026.

Leukemia Stem Cell-based Assay to Predict Relapse and Survival in AML Patients With MLL-Rearrangement

NIH's ClinicalTrials.gov has registered an observational study (NCT07537738) examining whether leukemia stem cell detection via multiparameter flow cytometry can predict relapse in acute myeloid leukemia patients with MLL-rearrangement. The study will detect leukemia stem cells alongside minimal residual disease monitoring using bone marrow samples. Participants are AML patients undergoing regular medical care who will have stem cell detection performed concurrently with their existing MRD testing protocols.

Phase 2 Leucine Diet Trial Combined With Chemoimmunotherapy for Advanced Gastric Cancer

NIH ClinicalTrials.gov registered a Phase 2 study (NCT07537348) evaluating a leucine-restricted diet combined with chemotherapy and immunotherapy in patients with advanced gastric cancer. The trial will assess safety, tolerability, tumor response rates, and 1-year survival outcomes. No compliance obligations or regulatory actions are imposed by this registry entry.

Microbiota in OAB, DUI Children, Healthy Controls Compared

NIH has registered observational study NCT07535619 on ClinicalTrials.gov to investigate whether voided urinary, perineal/preputial, and fecal microbiota differ between children with Overactive Bladder (OAB) and Daytime Urinary Incontinence (DUI) compared to age- and gender-matched healthy controls. The study will also assess whether microbiota composition varies by DUI severity and changes throughout treatment.

Effect of Simulation-Based Vaginal Examination Training on Anxiety, Confidence, and Skills in Midwifery Students

NIH's ClinicalTrials.gov registered a randomized controlled quasi-experimental study (NCT07535255) investigating the effects of simulation-based vaginal examination training on skill performance, anxiety, and satisfaction in 67 third-year midwifery students at a state university in Turkey. Results showed simulation training significantly reduced state anxiety in both clinical and laboratory groups (p<0.001) and laboratory group students demonstrated improvements in satisfaction and self-confidence (p<0.05). Clinical group students achieved significantly higher vaginal examination skill scores compared to the laboratory group (p<0.001).

Baricitinib Phase 1b/2 Trial for Post-HSCT Persistent Thrombocytopenia

NIH registered a Phase 1b/2 clinical trial (NCT07535645) on ClinicalTrials.gov studying baricitinib in patients with thrombopoietin-receptor-agonist-refractory persistent thrombocytopenia following allogeneic hematopoietic stem cell transplantation. The prospective, open-label trial will evaluate safety and efficacy profiles of the JAK inhibitor intervention.

VENEZE Peptide Hair Serum vs 2% Minoxidil for Androgenetic Alopecia

NIH registered a randomized, double-blind Phase 4 clinical trial (NCT07536100) comparing VENEZE peptide hair serum to topical 2% minoxidil in approximately 300 patients with androgenetic alopecia. Participants will be assessed for changes in hair density, hair thickness, and treatment tolerability over the study period. The trial aims to evaluate whether a peptide-based serum offers a viable alternative to standard minoxidil therapy.

Effect of Myopia-Control Contact Lenses in New Zealand Chinese Children

NIH registered Phase 3 clinical trial NCT07535749 evaluating myopia progression control using MiSight 1 Day (CooperVision) and Abiliti 1-Day (Johnson & Johnson VisionCare) contact lenses in New Zealand Chinese children. The 6-month randomized controlled paired-eye study will enroll participants at Auckland Myopia Clinic with assessments at baseline, 2 weeks, 3 months, and 6 months.

Expanded Access Program for Leronlimab in Metastatic TNBC

NIH's ClinicalTrials.gov registered an Expanded Access Program for investigational leronlimab (PRO 140) in metastatic triple-negative breast cancer, offering a pathway for patients lacking satisfactory treatment options and unable to enroll in clinical trials. The observational, open-label study documents program eligibility, interventions, and study design. No new compliance obligations are created for sponsors, healthcare providers, or patients.

Prospective Exploration of Vascular Complications Associated With Immune Checkpoint Inhibitors

NIH registered an observational study (NCT07535944) on ClinicalTrials.gov to explore vascular complications associated with immune checkpoint inhibitors (ICIs). The study will evaluate the vascular impact of ICIs such as nivolumab, pembrolizumab, and atezolizumab in cancer patients. ICIs have been linked to immune-mediated toxicities affecting various organ systems, including the cardiovascular system, though vascular complications remain poorly understood.

NCT07535723: Botulinum Toxin and GON Block for Chronic Migraine

A new randomized controlled trial (NCT07535723) was registered on ClinicalTrials.gov evaluating the combination of OnabotulinumtoxinA (Botox) injections with Greater Occipital Nerve (GON) block versus single therapy for chronic migraine patients. The trial will assess improvements in headache frequency, severity, and quality of life. Enrollment target and sponsor details were not specified in the registration record.

Phase 4 Adenosine Pre-Medication in Primary PCI Randomized Control Trial

NIH registered a Phase 4 clinical trial (NCT07536802) evaluating adenosine pre-medication versus standard care in primary percutaneous coronary intervention for ST-segment elevation myocardial infarction patients. The randomized controlled trial aims to assess impact on slow flow/no-reflow phenomenon incidence. The trial is registered on ClinicalTrials.gov.

Observational Falls Validation Study for Traumatic Brain Bleeding

NIH registered an observational study (NCT07536906) to validate a rapid bedside decision rule guiding emergency physicians on when older adults should receive brain scans to diagnose traumatic brain bleeding. The study addresses falls in adults over 65, which result in 500,000 Canadian emergency department visits annually. Researchers will assess whether the clinical decision rule effectively identifies patients requiring imaging for intracranial bleed detection.

Qualitative Study of Care Perceptions in Chemotherapy Patients

NIH registered an observational qualitative study (NCT07536945) on individualized care perceptions among outpatient chemotherapy patients at Yalova Training and Research Hospital in Turkey. The study will interview 10 to 20 participants over age 18 to understand how personalized nursing care affects symptom management and treatment adherence. Research will be conducted from May 2026 through April 2027.

Lidocaine Spray for Postoperative Shoulder Pain in Laparoscopic Surgery

ClinicalTrials.gov registered a randomized controlled trial (NCT07537127) at Peking Union Medical College Hospital evaluating 0.08% lidocaine spray for postoperative shoulder pain in 100 patients undergoing single-port laparoscopic gynecological surgery. The experimental group receives 50ml lidocaine sprayed on bilateral subdiaphragmatic regions; the control group receives standard ERAS protocol. Primary endpoint is NRS pain score at 6 hours postoperatively. Estimated primary completion date is April 17, 2026.

Prophylactic Anti-epileptic Regimen in Traumatic Brain Injury

NIH registered an observational clinical trial (NCT07535736) evaluating the effectiveness and safety of anti-epileptic drugs in preventing early and late post-traumatic seizures among patients with traumatic brain injury. The study will assess antiepileptic efficacy and safety outcomes in this patient population.

Effect of Low-Power Laser Therapy on Pain and Functional Outcomes in Patients With Thoracic Outlet Syndrome

NIH's ClinicalTrials.gov registered a new randomized controlled study (NCT07535853) evaluating low-power laser therapy combined with physical therapy versus conventional treatment alone for thoracic outlet syndrome patients. The trial aims to determine whether adding laser therapy provides superior pain relief and improves daily physical functions. The study carries an anticipated start date of April 17, 2026.

Phase 4 Dulaglutide Triple Therapy for T2DM Chronic Kidney Disease

A Phase 4 clinical trial (NCT07537088) has been registered on ClinicalTrials.gov evaluating dulaglutide as add-on therapy for Chinese adults with Type 2 Diabetes and Chronic Kidney Disease. The 26-week randomized study will assess whether adding dulaglutide to existing SGLT2 inhibitor plus finerenone therapy provides additional kidney protection. Participants must have been on stable combination therapy for at least 3 months before enrollment.

Phase I/II Clinical Trial for HS_SW01 Cells Injection in Systemic Sclerosis

The National Institutes of Health registered a Phase I/II clinical trial (NCT07535931) on ClinicalTrials.gov to evaluate the safety, tolerability, pharmacokinetics, and immunological profile of HS_SW01 human umbilical cord mesenchymal stem cell injection in patients with systemic sclerosis. The single-arm, open-label trial will enroll participants who meet specified inclusion and exclusion criteria following informed consent. No regulatory approvals or compliance deadlines are established by this registration notice.

Relief Efficacy of Lidocaine Versus Morphine for Acute Renal Colic in the Emergency Department

NIH has registered a new clinical trial (NCT07536594) on ClinicalTrials.gov comparing intravenous lidocaine to morphine for acute renal colic pain management in emergency departments. The trial aims to address the opioid epidemic by investigating whether lidocaine can serve as an effective non-opioid alternative for pain management. Researchers plan to recruit a diverse population to build on preliminary evidence from a 2012 Iranian study.

Effect of Complete Suction-Induced Collapse of Renal Collecting System at End of RIRS on Early Postoperative Outcomes

NIH ClinicalTrials.gov has registered NCT07535281, a randomized controlled trial evaluating whether actively suctioning the renal collecting system to induce collapse at the end of retrograde intrarenal surgery (RIRS) reduces postoperative pain and infection in kidney stone patients. Participants will be randomly assigned to experimental group (suction-induced collapse) or control group (standard drainage). The study aims to determine if this surgical modification improves early recovery outcomes and patient satisfaction.

Michigan Awards Healthy Kids Dental Contract to Delta Dental of Michigan

Michigan DHHS awarded the Healthy Kids Dental (HKD) contract to Delta Dental of Michigan. The program covers approximately 955,000 children under age 21 enrolled in Medicaid. The five-year contract begins October 1, 2026, with three one-year extension options.

Measles Case in Saluda County Adult, 34 Exposed

South Carolina DPH confirmed a measles case in a Saluda County adult linked to international travel. Lab confirmation was received April 16. Thirty-four individuals have been identified as potentially exposed and are being notified for quarantine. No public exposures occurred. This brings the state total to 1,001 measles cases since July 2025, while the unrelated Upstate outbreak (997 cases) is scheduled to be declared over April 26.

Co-supplementation With Bifidobacterium Longum W11 and Colopectin for Maintenance Therapy in Children With Functional Constipation

The NIH ClinicalTrials.gov registry has recorded a new randomized, double-blind, placebo-controlled trial (NCT07536698) evaluating co-supplementation with Bifidobacterium longum W11 and Colopectin for maintenance therapy in children aged 2 to 6 years with functional constipation receiving macrogol. The study will enroll participants for 4 weeks of active treatment followed by 4 weeks of follow-up after treatment discontinuation, assessing constipation persistence, stool consistency, evacuation distress, soiling episodes, and treatment compliance.

Seven-Year Radiographic Retention Study, Four Implant Overdenture

NIH's ClinicalTrials.gov registered a retrospective observational study (NCT07536776) examining marginal bone loss and retention outcomes in 27 completely edentulous patients receiving four-implant LOCATOR-retained mandibular overdentures over a seven-year follow-up period. The study assesses bone loss and retention at baseline, one year, and seven years post-insertion. Enrollment opens April 17, 2026.

Observational Study Recording Stress Biomarkers in Autism Spectrum Disorders

The National Institutes of Health registered an observational clinical trial (NCT07535801) studying how physiological stress signals differ between children and young people with autism spectrum disorder (ASD) and non-ASD participants. The study will monitor two biological stress systems — the autonomic nervous system and the hypothalamic-pituitary-adrenal axis — in real-life environments including schools, homes, and care institutions. Participants with ASD who also have intellectual deficiency will be compared against a control group of typically developing peers.

Auricular Point Stimulation Plus Dexamethasone for Chemotherapy Nausea

NIH registered a Phase 2 clinical trial (NCT07537660) on ClinicalTrials.gov evaluating auricular point stimulation combined with dexamethasone for preventing chemotherapy-induced nausea and vomiting in pancreatic cancer patients receiving gemcitabine plus paclitaxel protein-bound treatment. The trial aims to enroll participants who will receive auricular acupressure with bean seeds plus IV dexamethasone as an antiemetic, with a primary completion date of April 17, 2026.

GEA Simultaneous to VSG Reduces Post-operative GERD

NIH registered a clinical trial (NCT07537244) to evaluate whether adding gastroenteroanastomosis (GEA) to vertical sleeve gastrectomy (VSG) reduces post-operative gastroesophageal reflux disease (GERD) in obese patients. The randomized study will compare Group A (VSG with GEA) versus Group B (VSG without GEA) using symptom questionnaires during follow-up visits. All exams are part of standard surgical or GERD follow-up routines, with an estimated start date of April 17, 2026.

Prostate Cancer Hot Flashes ADT Smartwatch Feasibility Study

NIH ClinicalTrials.gov registered a new feasibility study (NCT07535541) titled 'A Feasibility Study of Biometric Measurements Via Wearable Smart Watch Technology for Evaluation of Vasomotor Symptoms in Patients Treated With Androgen Deprivation Therapy for Prostate Cancer.' The study will evaluate whether prostate cancer patients on ADT with vasomotor symptoms (hot flashes) consistently wear a smartwatch device to track health data and log hot flashes. Participants will wear the smartwatch for 4 weeks and complete surveys about their hot flash experiences. No compliance obligations are created for organizations.

Phase 4 Randomized Trial of Indomethacin and Paracetamol for Pain Management During IVF Oocyte Retrieval

NIH registered a Phase 4 randomized controlled trial (NCT07536425) evaluating preoperative Indomethacin (100 mg per rectum) and Paracetamol/Acamol (1,000 mg intravenously) for pain management during oocyte retrieval in women undergoing IVF or ICSI. The trial will study pain outcomes in women receiving these analgesic interventions. Conditions include Pain and Oocyte Retrieval. This is an informational clinical trial registration on ClinicalTrials.gov.

NCT07537569: Preoperative Oncogeriatric Assessment in Hepatectomy Patients

NIH registered clinical trial NCT07537569, a prospective study examining comprehensive geriatric assessment (CGA) in older adults scheduled for hepatectomy due to hepatic malignancies. The study aims to optimize perioperative care and improve surgical safety and recovery outcomes in elderly patients. Conditions include hepatic malignancies and comprehensive geriatric assessment with CGA as the sole intervention type.

Extended Time Window IV Thrombolysis Registry for Acute Ischemic Stroke

The NIH registered a new observational study (NCT07536074) titled EXTEND-IVT Registry on ClinicalTrials.gov. The study will evaluate the effectiveness and safety of intravenous thrombolysis administered beyond 4.5 hours after last known well in patients with acute ischemic stroke. The prospective, multicenter, observational cohort study will be conducted in routine clinical practice settings across China.

Boil Water Advisory Rescinded for City of Humboldt, Allen County, Kansas

The Kansas Department of Health and Environment (KDHE) has rescinded a boil water advisory for the City of Humboldt public water supply system in Allen County. The advisory was originally issued due to a loss of pressure, which may result in loss of chlorine residuals and bacterial contamination. Laboratory testing of drinking water samples collected from the City of Humboldt indicates no evidence of bacteriological contamination, and all conditions that placed the system at risk are resolved.

Amgen Antigen Binding Proteins Targeting Beta-Klotho and FGF Receptors

The European Patent Office granted Amgen Inc. Patent EP3760642A1 covering human antigen binding proteins that bind beta-Klotho, FGF receptors, and complexes thereof. The patent covers therapeutic applications including treatment of metabolic conditions (A61P 3/04). The patent is designated for all 31 European states including DE, FR, GB, IT, ES, NL, SE, and 21 others.

European Patent for Kava-Derived Therapeutic Compounds and Methods of Use Thereof

EPO granted patent EP3068416A1 to Kuality Herbceutics LLC and 9 named inventors for kava-derived therapeutic compounds and methods of use. The invention is classified under IPC codes A61K 31/12, A61K 31/353, A61K 31/366 (therapeutic compounds) and A61P 35/00 (cancer treatment). The patent is designated in 36 European states including Germany, France, UK, Italy, Spain, Netherlands, Belgium, Austria, and Switzerland.

Bifunctional BTK Degrading Compounds Via Ubiquitin Proteasome Pathway

The European Patent Office published patent EP3924350A1, granted to Nurix Therapeutics, Inc., covering bifunctional compounds for degrading BTK via the ubiquitin proteasome pathway. The patent application includes six IPC classifications spanning pharmaceutical compositions and therapeutic methods. Protection extends across 31 designated European states including major markets.

UPAR Targeting Peptide for Peroperative Optical Imaging of Invasive Cancer

The EPO published patent application EP3733215A1 for Fluoguide A/S, covering a UPAR targeting peptide for peroperative optical imaging of invasive cancer. The patent names Andreas Kjaer and Morten Persson as inventors and includes designations across multiple European member states including DE, FR, GB, IT, ES, NL, and others. This publication grants intellectual property protection for the novel peptide composition and its diagnostic use in cancer surgery.

D3 Receptor Agonist Compounds; Methods of Preparation; Intermediates Thereof; and Methods of Use Thereof

EPO published patent application EP3953350A1 for D3 receptor agonist compounds filed by the United States Department of Health and Human Services. The patent covers specific chemical compounds, methods of preparation, intermediates thereof, and methods of therapeutic use.

DLL3 Targeting Chimeric Antigen Receptors and Binding Agents

EPO published patent application EP3930744A1 by Allogene Therapeutics Inc. and Pfizer Inc. for DLL3 targeting chimeric antigen receptors (CARs) and binding agents. The application classified under A61K 39/00, A61P 35/00, and C07K 16/28 covers therapeutic compositions targeting DLL3 for cancer treatment. The patent designates 31 European states including Germany, France, the United Kingdom, Italy, Spain, and other EU member states.

Neurotrophin Binding Protein p75NTR for Osteoarthritis Treatment - Patent EP3169347A1

The European Patent Office published patent application EP3169347A1 on April 8, 2026, covering neurotrophin binding protein p75NTR for use in treating osteoarthritis. Applicant Levicept Limited, invented by Simon Westbrook, received European patent protection covering A61K therapeutic compositions. The patent designates all EPC contracting states including AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, and TR.

Lonza Ltd Patents Larch Tree Arabinogalactan-Polyphenol Composition

The European Patent Office published patent application EP2638914A1 filed by Lonza Ltd, covering a composition comprising arabinogalactan and polyphenols derived from larch trees. The application, filed by inventors Freitas and Rodriguez, is classified under IPC codes A61K 36/13, A61P 31/00, and A61P 31/12, indicating therapeutic anti-infective applications. The patent designates all EU member states and additional European countries.

Integrin Alpha10 Patent for Aggressive Cancer Treatment

The European Patent Office published patent application EP3956360A1 for Integrin Alpha10 compositions and methods for treating aggressive cancer forms. Applicant Targinta AB seeks protection across 37 designated European states. The patent covers anti-integrin alpha10 antibodies and therapeutic applications for cancer treatment.

Engineered High-Affinity Human T Cell Receptors - EP3071594A1

The European Patent Office published patent application EP3071594A1 for engineered high-affinity human T cell receptors, filed by the Board of Trustees of the University of Illinois. The invention relates to engineered high-affinity human T cell receptors (TCRs) with applications in cancer immunotherapy. The application is classified under C07K 14/725, A61K 38/17, and A61P 35/00, with designation extending to all EU member states plus other European countries.

tDCS Stroke Rehabilitation Observational Study, Apr 17

This NIH ClinicalTrials.gov registry entry documents observational study NCT07535788 examining implementation of transcranial Direct Current Stimulation (tDCS) in inpatient and outpatient rehabilitation settings for stroke patients with aphasia. The study evaluates whether tDCS can be effectively integrated with routine speech therapy.

Phase 1/2a Trial of NWRD09 for Persistent HPV16 Infection in Female Participants

The NIH ClinicalTrials.gov registry has posted a new Phase 1/2a clinical trial (NCT07536282) evaluating NWRD09, an investigational drug, for the treatment of persistent HPV16 infection in female participants. The two-part study will assess safety, tolerability, immunogenicity, and efficacy while determining the maximum tolerated dose and recommended Phase 2 dose. Participants will receive either NWRD09 or placebo as part of the study design.

Williams Syndrome iPSC Oligodendrocyte Study

NIH's ClinicalTrials.gov has registered NCT07537374, a case-control observational study examining oligodendrocyte lineage development in children with Williams syndrome using peripheral blood-derived iPSC models. The study plans to enroll 3 children with Williams syndrome and 3 healthy controls, with samples induced into neural progenitor cells and oligodendrocyte lineage cells for in vitro studies of myelin-related gene programs and developmental trajectories.

Phase 4 Cardiac Surgery Ketamine Anti-inflammatory Trial NCT07536633

NIH ClinicalTrials.gov registered a Phase 4 clinical trial (NCT07536633) investigating the anti-inflammatory effect of ketamine in cardiac surgery patients. The randomized controlled study will evaluate intraoperative ketamine administration (1 mg/kg induction plus 2.4 mg/kg/h maintenance infusion) versus control on inflammatory markers including neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, and C-reactive protein. The trial targets adult cardiac surgery patients and will assess pain scores, hospital mortality, and morbidity outcomes.

Prospective Longitudinal EVOH Renal Embolization Study in ADPKD

NIH has registered a prospective longitudinal observational study (NCT07535385) evaluating the radiological and clinical outcomes of renal embolization using ethylene-vinyl alcohol copolymer (EVOH) in dialysis patients with autosomal dominant polycystic kidney disease (ADPKD). The study aims to assess renal volume changes, complications, and prognostic factors in affected patients. Results may inform treatment strategies for ADPKD-related renal failure.

Phase 4 Antihistamine Trial for HTR Prevention in 40 Children, NCT07536152

NIH registered a Phase 4 randomized, double-blinded, placebo-controlled clinical trial (NCT07536152) at a university hospital evaluating intravenous antihistamine (chlorpheniramine) versus placebo for prevention of blood transfusion-associated adverse reactions in 40 children undergoing elective congenital heart defect repair with blood-primed cardiopulmonary bypass. The study will randomly assign 20 patients per group to receive a single dose immediately after separation from bypass prior to protamine administration.

Quadro-Iliac Plane Block vs Erector Spinae Plane Block After Total Hip Arthroplasty

NIH's ClinicalTrials.gov registered a new comparative clinical study (NCT07537036) evaluating the analgesic efficacy of Quadro-Iliac Plane Block versus Erector Spinae Plane Block in patients undergoing total hip arthroplasty. The interventional study will assign participants to receive one of two regional anesthesia techniques. This trial registration provides public transparency on ongoing medical research but does not establish regulatory compliance obligations.

Trans-septal Quilting Suturing vs Intranasal Silicone Splinting in Septoplasty

NIH ClinicalTrials.gov registered a randomized controlled trial (NCT07537920) comparing trans-septal quilting suturing versus intranasal silicone splinting following septoplasty in patients with deviated nasal septum. The study aims to identify which post-operative technique results in fewer adverse effects. Participants will be enrolled with an estimated completion date of April 2026.

Scalable Behavioral Program for Weight Loss Maintenance After GLP-1 and Anti-Obesity Medication Discontinuation

NIH registered clinical trial NCT07535892, a single-site pilot randomized controlled trial using a 2×2×2 factorial design to evaluate a multi-component behavioral intervention for weight loss maintenance following discontinuation of GLP-1 and anti-obesity medications. The trial will enroll participants randomized to a standardized 10-week foundational weight loss maintenance program combined with candidate support components including medically tailored meals, YMCA membership, and a structured mind-based program, with six-month follow-up.

Acute Medical Unit Study, Singapore, Apr 17

NIH's ClinicalTrials.gov registered observational study NCT07536035 evaluating Acute Medical Unit care models versus standard hospital care for patients with acute medical illnesses including falls, COPD, infection, asthma, pneumonia, UTI, and URTI. The 4-year study based in Singapore will measure hospital length of stay, emergency department utilization, health quality outcomes, and cost differences across care delivery models.

Ego-Tucking: Exploring Psychological Mechanisms of Fo-xi Phenomenon Among University Students

The NIH registered observational study NCT07536711 on ClinicalTrials.gov examining psychological mechanisms, stress, and mental fatigue among university students. The cross-sectional study uses a structured questionnaire to explore individual experiences, family dynamics, and macro-social environments contributing to behavioral changes in academic and professional competition contexts.

PD-1 Plus Lenvatinib vs Regorafenib for Unresectable Hepatocellular Carcinoma

NIH ClinicalTrials.gov registered a new Phase 2/3 clinical trial (NCT07537985) comparing the efficacy and safety of PD-1 inhibitor combined with Lenvatinib versus PD-1 inhibitor combined with Regorafenib for unresectable hepatocellular carcinoma (UHCC) after failure of first-line treatment with bevacizumab plus sintilimab. The study aims to provide evidence-based guidance for selecting optimal second-line treatment regimens. Estimated enrollment and completion date are listed in the registry.

High-flow Nasal Cannula Versus Conventional Oxygen Therapy in High-altitude Pulmonary Edema

NIH has registered Clinical Trial NCT07536477, a randomized controlled study evaluating High-flow Nasal Cannula Oxygen Therapy (HFNC) versus Conventional Oxygen Therapy (COT) in patients with High-Altitude Pulmonary Edema (HAPE). The single-center trial plans to enroll 168 participants, with an estimated completion date of April 17, 2026. HFNC is the sole intervention under investigation.

SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer

NIH's ClinicalTrials.gov has registered a new Phase 2 clinical trial (NCT07535632) at Zhongshan Hospital, Fudan University in China. The trial will study stereotactic body radiotherapy (SBRT) combined with sintilimab, bevacizumab, and TAS-102 as third-line therapy for 58 patients with recurrent or metastatic colorectal cancer. The 24-month study has a primary endpoint of progression-free survival.

Risk Factors and Prediction Model for Liver-Related Outcomes in Elderly Patients With Steatotic Liver Disease

NIH registered a retrospective cohort study (NCT07537829) on steatotic liver disease in elderly patients. The single-center observational study will analyze approximately 10,000 participants aged 60 and older from the Nanjing Elderly Steatotic Liver Disease Cohort to investigate liver-related and extrahepatic adverse outcomes. Risk prediction models will be developed using machine learning algorithms; no intervention is involved.

Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS

NIH registered an observational clinical trial (NCT07535242) investigating whether serum biomarkers GFAP, NfL, and VEGF serve as indicators of clinical progression in progressive multiple sclerosis. The study aims to better understand MS pathophysiology through biomarker analysis. This registry entry provides transparency on ongoing research but imposes no regulatory obligations on affected parties.

ESP Block Trial for Postoperative Spinal Pain Relief

NIH registered clinical trial NCT07537647, titled 'The Effect of Bilateral Erector Spina Plane Block on Postoperative Pain in Spinal Surgery.' The trial studies whether ultrasound-guided ESP block with bupivacaine reduces postoperative pain in patients undergoing lumbar spinal stabilization surgery. The study was registered on ClinicalTrials.gov and is listed as not yet recruiting with an estimated completion date of April 17, 2026.

Lullabies and White Noise Breastfeeding Study

NIH registered clinical trial NCT07537218 on ClinicalTrials.gov. The randomized controlled experimental study examines the effect of lullabies and white noise on breastfeeding success in newborns. The study enrolled 160 newborns divided into four groups: female voice lullaby, male voice lullaby, white noise, and control, with data collected using the LATCH Breastfeeding Assessment Scale.

Sleep Quality, Cognition, and Disease Severity in Parkinson's Disease - NCT07536490

The NIH National Library of Medicine registered an observational study (NCT07536490) on ClinicalTrials.gov investigating the relationship between sleep quality, cognitive function, and disease severity in individuals with Parkinson's disease. The single-session study will assess participants using standardized tools including the Stroop Test, Clock Drawing Test, Montreal Cognitive Assessment, Unified Parkinson's Disease Rating Scale, and Modified Hoehn and Yahr Scale. The study enrolls participants diagnosed with Parkinson Disease.

Efficacy of Multi-Type Photolithography Flat Microstructure Lenses for Childhood Myopia Control

NIH ClinicalTrials.gov registered a clinical trial (NCT07535658) studying photolithography flat microstructure lenses for childhood myopia prevention and control. The randomized controlled trial will compare plano microstructure lenses with multi-point defocus design against Spectacle Lenses with Aspherical Lenslets (Essilor Stellest) in children over a 1-year period.

Ivonescimab With Dato-DXd or Osimertinib Phase 1

NIH ClinicalTrials.gov registered Phase 1 trial NCT07535437 evaluating ivonescimab in combination with Dato-DXd or osimertinib for treatment of EGFR-mutated non-small cell lung cancer. The dose-escalation study will assess safety and tolerability to determine optimal dosing. Participants with NSCLC harboring EGFR mutations will receive fixed-dose ivonescimab with escalating doses of either Dato-DXd or osimertinib.

Decision Aid Efficacy in Low Risk Thyroid Cancer

NIH ClinicalTrials.gov registered a clinical trial (NCT07536412) evaluating whether a decision aid pamphlet reduces decision anxiety and improves treatment decision readiness in low-risk thyroid cancer patients. The study will enroll patients diagnosed with differentiated thyroid cancer, papillary thyroid microcarcinoma, or papillary thyroid carcinoma to receive the decision aid before meeting with a surgeon. The intervention provides information about three treatment options (total thyroidectomy, partial thyroidectomy, or active surveillance) and questions for patients to ask their surgeon.

NAUTILUS Project Develops Mutation-Specific ASO for Syndromic Craniosynostoses

NIH ClinicalTrials.gov registered observational study NCT07535372 for the NAUTILUS project, developing ultra-personalized antisense oligonucleotide (ASO) therapeutics for syndromic craniosynostoses. The study targets rare genetic conditions including Crouzon, Saethre-Chotzen, Muenke, Pfeiffer, and Apert syndromes caused by FGFR1/2/3, TWIST1, and TCF12 variants. ASO design will be patient-tailored to silence gain-of-function alleles or restore expression in loss-of-function contexts.

Wildfire Smoke Lung Health Study, Canada, Asthma COPD

NIH registered a clinical trial (NCT07536178) titled 'Lungs on Fire' to study how wildfire smoke exposure contributes to long-term lung disease in susceptible populations. The controlled human exposure study will test varying concentrations of woodsmoke from Lodgepole Pine on participants with asthma, COPD, and lung cancer in Canada. The research aims to identify health impacts, vulnerable populations, and biological changes leading to chronic illness.

At-Home taVNS for Neurorehabilitation in Parkinson's Disease

NIH registered a new clinical trial (NCT07536022) evaluating at-home transcutaneous auricular vagus nerve stimulation (taVNS) for neurorehabilitation in approximately 40 adults with Parkinson's Disease. The 8-week study will assess feasibility, tolerability, and preliminary efficacy of self-administered daily 1-hour taVNS sessions using a threshold-based individual dosing protocol. Secondary objectives include measuring changes in motor and non-motor symptoms and examining neural network connectivity via MRI.

Observational Study of Language Reorganization in AVM Patients

NIH registered observational clinical trial NCT07537504 on ClinicalTrials.gov. The study investigates language function reorganization in patients with brain arteriovenous malformations (AVMs) involving language areas. Researchers will use multimodal MRI to examine functional remodeling, white matter pathway remodeling, and structural remodeling from multiple dimensions. The study aims to elaborate the role of the right cerebral hemisphere in reorganized language networks and interhemispheric interaction mechanisms.

Monocyte Ratios, APRs, and Sepsis ICU Study

NIH's ClinicalTrials.gov registered a new observational study (NCT07537179) examining whether monocyte distribution, monocyte-to-lymphocyte ratio, and neutrophil-to-lymphocyte ratio can serve as biomarkers in sepsis patients in the ICU. The study will enroll patients admitted to the ICU for sepsis or those who develop sepsis during hospitalization, comparing these ratios with conventional acute phase response biomarkers.

Phase 2 Trial for Intestinal Fluid Reinfusion Prevention of Low Anterior Resection Syndrome

NIH registered a Phase 2 clinical trial (NCT07537998) on ClinicalTrials.gov to evaluate antegrade intestinal fluid reinfusion for prevention of low anterior resection syndrome in patients with prophylactic ileal stoma. The single-center, prospective randomized controlled trial will compare intestinal fluid infusion to potable water infusion in approximately 60 participants. Participants will receive the assigned intervention at 1 month post-rectal resection until ileostomy reversal and maintain symptom diaries.

Controllable Insertion Sleeve with Guide and Control Wires

USPTO granted Patent US12599749B2 to Kardion GmbH for a controllable insertion sleeve with a guide wire extending through a cavity in the sleeve wall and at least one control wire integrated into the sleeve wall to cause curvature. The patent, with 11 claims, covers CPC classifications A61M 25/0147 and related categories. Filing date was May 30, 2019 (Application No. 17056937).

US Patent 12599757B2 - Fabrication Method for Complex 3D Microscale Structures

The USPTO granted Patent 12599757B2 to The Charles Stark Draper Laboratory, Inc. on April 14, 2026, covering a bilayer mold fabrication method for forming polymer and metal microstructures. The invention enables creation of complex re-entrant 3D microscale structures using laser-etching of metallic foil and plastic elastic polymer materials. Six claims were granted.

Splitable Catheter Docking Station System and Method

USPTO granted patent US12599752B2 to Bard Access Systems, Inc. covering a splitable catheter docking station system for rapid insertion central catheters (RICC). The patent protects a two-step insertion system featuring a docking station that detaches from an introducer placement system, with design elements including guidewire hub, collapsible sterile barriers, and locking features to prevent premature advancement.

Methods of Preventing Platelet Alloimmunization and Alloimmune Platelet Refractoriness in Transfused Recipients

USPTO granted patent US12599667B2 to BLOODWORKS for methods of preventing platelet alloimmunization and alloimmune platelet refractoriness in transfused recipients. The patent covers modifying donor whole blood or platelets prior to transfusion to prevent or reduce transfusion-associated complications. The patent includes 15 claims and was filed on September 28, 2022.

Composition Comprising Three-Dimensional Astrocyte Bundles and Methods of Making and Using

The USPTO granted Patent US12599670B2 to the Trustees of the University of Pennsylvania covering compositions comprising three-dimensional astrocyte bundles with bipolar and aligned astrocyte processes, methods of making such compositions through ex vivo machine-driven physical stretching or growth within hydrogel micro-columns, and methods of treating nervous system injury or degeneration by implanting the compositions. The patent contains 25 claims and lists D. Kacy Cullen as inventor.

Guidewire Assembly With Intertwined Core Wire, Acclarent, Inc.

USPTO granted patent US12599754B2 to Acclarent, Inc. for a guidewire assembly featuring a helical wire coil and a non-extensible core wire that is intertwined with the coil to inhibit longitudinal elongation. The patent, with 20 claims, was filed March 21, 2022 under Application No. 17699225.

Vascular Access Connector Support Device, Systems, and Methods

USPTO granted Patent US12599750B2 to Becton, Dickinson and Company for a vascular access connector support device. The patent covers a catheter system including a connector support device that is wedge-shaped to support the connector at an insertion angle. The patent names Jonathan Karl Burkholz, Curtis H. Blanchard, and Weston F. Harding as inventors.

Vascular Catheter and Method - US12599755B2

USPTO granted patent US12599755B2 to I-VASC S.R.L. for a vascular catheter featuring occlusion elements and an expandable balloon between them. The catheter handle includes dual pumping devices with synchronization capabilities for fluid management. The patent contains 17 claims covering the catheter shaft, balloon mechanism, pumping system, and control handle.

KARDIUM Catheter Safety Release System, US12599747B2, Issued Apr 14, 2026

USPTO granted patent US12599747B2 to KARDIUM INC. on April 14, 2026. The patent covers medical device systems including a catheter sheath and shaft with an end effector, featuring a control element that can be severed to facilitate removal from bodily cavities. The invention also includes a liquid entry port for expedited fluid provision to distal portions. The patent contains 22 claims.

Bard Access Systems Catheter Tip Patent US12599748B2

The USPTO granted patent US12599748B2 to Bard Access Systems, Inc. on April 14, 2026, covering a rapidly insertable central catheter with a single-piece catheter tip design featuring uniform and non-uniform tapered sections for tissue dilation. Inventors are Glade H. Howell and Juan Sepulveda, with 16 claims allowed and application filed December 6, 2022.

V-Wave Interatrial Shunt Patent US12599756B2 Granted April 14

USPTO granted patent US12599756B2 to V-Wave Ltd. covering interatrial shunt devices with in vivo adjustable dimensions. The patent includes 14 claims for a body with shape-memory material defining a passageway through a neck region between atria, where first and second regions are superelastic at body temperature and the neck region is malleable for flow adjustment.

Method for Preparing Hemogenic Endothelium Cell and Hematopoietic Stem Cell

USPTO granted Patent US12600954B2 to Allife Medicine (Beijing) Limited on April 14, 2026, covering methods for preparing hematopoietic endothelial cells and hematopoietic stem cells or hematopoietic stem and progenitor cells. The methods use transcription factors LCOR, HOXA9, HOXA5, RUNX1, and ERG during induced pluripotent stem cell differentiation. The patent application was filed March 19, 2025, and contains 11 claims.

US12600990B2 - mRNA Induced Expression of BMP and Receptor and Methods Related Thereto

USPTO granted patent US12600990B2 to inventors Alexander Day and Bradford Mullin covering methods of preparing synthetic mRNA encoding bone morphogenic protein (BMP) and/or BMP receptor in lipid-solubilized carriers for intraoperative delivery to bone fusion beds. The patent includes 20 claims and covers CPC classifications including C12N 15/88, A61K 47/543, A61K 48/0041, and C07K 14/51.

Method of Determining or Influencing Chondrogenic Potential of Mesenchymal Stromal Cells

USPTO granted Patent US12600952B2 to AO TECHNOLOGY AG on April 14, 2026. The patent covers methods of increasing chondrogenic potential of mesenchymal stromal cells (MSCs) by manipulating TGFβR1, TGFβR2, and ACVRL1 expression levels. The patent contains 23 claims and has 5 CPC classifications spanning cell therapy and peptide technologies.

AB Enzymes Xylanase Variants - Patent US12600960B2

The USPTO granted Patent US12600960B2 to AB Enzymes Finland Oy for xylanase variant polypeptides comprising amino acid sequences with at least 79% but less than 100% identity to SEQ ID NO: 1, featuring at least one disulfide bridge and amino acid substitutions at positions 23 and/or 28. The patent covers the variant polypeptide, fusion proteins, enzyme compositions, recombinant host cells for production, and methods of use.

Carbohydrate Binding Module Variants and Hybrid Polypeptides Comprising Same

USPTO granted Patent US12600996B2 to Novozymes A/S on April 14, 2026, covering cellobiohydrolase variants and carbohydrate binding module variants. The patent also protects polynucleotides encoding the variants, nucleic acid constructs, vectors, host cells, and associated production methods. The patent contains 33 claims and was filed under application number 17812259.

Multiplex Genome Editing of Immune Cells for Enhanced Functionality and Resistance to Suppressive Environment

The USPTO granted patent US12600944B2 to the Board of Regents, The University of Texas System covering methods for multiplex genome editing of immune cells, including disruption of multiple genes and insertion of chimeric antigen receptors at specific gene loci. The patent names Rafet Basar, Elizabeth Shpall, and Katy Rezvani as inventors and contains 14 claims. The filing date was November 27, 2019.

Beta Ketoacyl Synthase IV Variants by CORBION BIOTECH

USPTO granted Patent US12600994B2 to CORBION BIOTECH, INC. covering non-natural variant β-ketoacyl-ACP synthase (KAS) IVa enzymes, polynucleotides encoding such variants, host cells expressing such variants, and oils and oil products produced by such cells. The patent names Joshua Ferreira, Janice Lau Wee, and Nien-Hsi Ko as inventors. Filing date was January 15, 2021, with 21 claims granted.

Fusion Protein Enzyme for Biocatalytic Reduction of Cystine to Cysteine

USPTO granted patent US12600995B2 to Wacker Chemie AG for a fusion protein enzyme combining thioredoxin and thioredoxin reductase activities from E. coli to catalyze the reduction of cystine to cysteine. The patent contains 7 claims and was assigned CPC classifications related to biochemistry and peptide chemistry.

ELTA Patent - Enzymatic ADP-ribose Labeling Methods

USPTO granted patent US12601734B2 to Johns Hopkins University covering ELTA (Enzymatic Labeling of Terminal ADP-ribose) technology for labeling free, protein-conjugated, or nucleic acid-conjugated ADP-ribose molecules at their 2'-OH termini. The patent contains 28 claims and covers applications including fluorescence-based biophysical measurement of PAR-protein interaction, detection of PAR length from cells, and enrichment of ADP-ribosylated peptides for mass spectrometry identification.

Probiotic Composition for Improving Soy Protein Proteolysis and Amino Acid Production Activity

USPTO granted patent US12599641B2 to Lactomason Co., Ltd. on April 14, 2026. The patent covers a probiotic composition that improves soy protein proteolysis and branched-chain amino acid production to prevent sarcopenia. The mixed bacterial strain formulation demonstrates enhanced self-aggregation, hydrophobicity, and intestinal adhesion compared to single-strain alternatives.

Phase 2 Naxitamab Neuroblastoma Trial, 10 Patients, Apr 17

NIH ClinicalTrials.gov registered Phase 2 trial NCT07537400 evaluating Naxitamab and GM-CSF chemoimmunotherapy combined with COG-type induction chemotherapy in 10 newly diagnosed high-risk neuroblastoma patients aged 12 months to 21 years. The trial aims to assess safety over approximately 2 years. This registration adds to the publicly available record of pediatric oncology clinical research.

Low-Level Diode Laser Therapy for Osseointegration Around Delayed Dental Implants

NIH ClinicalTrials.gov has registered a new clinical study (NCT07536451) evaluating the efficacy of Low-Level Diode Laser Therapy (LLDLT) on enhancing osseointegration and peri-implant mucosal tissue around delayed dental implants. The study will compare dental implant placement with LLDL intervention against standard dental implant placement without laser therapy. No compliance obligations or regulatory actions are imposed by this registration.

Food is Medicine in Pediatric Patients With Diabetes

The NIH ClinicalTrials.gov registry has published a randomized controlled trial (NCT07535502) evaluating Food is Medicine Programming through medically tailored pre-packaged meals for pediatric patients with Type 1 Diabetes. The study will assess whether medically-tailored meals combined with nutrition counseling improves clinical outcomes, decreases healthcare utilization, and improves health-related quality of life in children and adolescents with diabetes and potential food security concerns.

Microgreens on Sleep Architecture, Athletes

NIH registered clinical trial NCT07537140 on ClinicalTrials.gov investigating the effects of microgreen consumption on sleep architecture in athletes. The study will assess sleep onset latency, total sleep time, sleep efficiency, and NREM/REM distribution. The trial lists cabbage as the control intervention and an oral microgreen cocktail as the experimental intervention, with an anticipated completion date of April 17, 2026.

Ivonescimab, Chemotherapy, and SRS for Non-Small Cell Lung Cancer Brain Metastases

The NIH National Library of Medicine registered a Phase 1 clinical trial (NCT07535463) on ClinicalTrials.gov testing ivonescimab in combination with standard chemotherapy and stereotactic radiosurgery for patients with non-small cell lung cancer that has spread to the brain. The study aims to establish the safe dosage of ivonescimab in this combination regimen and evaluate its effectiveness in treating brain metastases. The trial is listed as Phase 1, indicating an early-stage safety and dosing study.

Phase 3 BMAC vs Corticosteroid for TMJ Pain

NIH registered a Phase 3 randomized clinical trial (NCT07536399) comparing Bone Marrow Aspirate Concentrate (BMAC) injection versus corticosteroid injection during TMJ arthroscopy for patients with temporomandibular joint pain unresponsive to conservative treatment. The trial will enroll participants randomized to receive either BMAC or corticosteroid injection, with 3 follow-up visits over 6 months and MRI imaging.

Phase 1 3D1015 Injection Trial for Metastatic Castration-Resistant Prostate Cancer

NIH registered a Phase 1 clinical trial (NCT07537010) investigating 3D1015 Injection (Lu 177-PSMA-3D1015) in adult males with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The open-label study will evaluate safety, tolerability, and dosimetry of intravenous infusions with dynamically individualized treatment regimens. Secondary objectives include assessing preliminary anti-tumor efficacy and optimal dosing.

VR Learning Program for Sexual-and-gender-diversity Care

NIH registered Clinical Trial NCT07535216 on ClinicalTrials.gov to study the effectiveness of a virtual reality (VR) learning program designed to improve nursing students' care practices for sexual and gender-diversity patients. The clinical trial will evaluate both short-term and long-term effects on caring behaviors. The study is listed with conditions including sex difference, virtual care, and nursing care, with an expected completion date of April 17, 2026.

Effect of Patient Education Program on Vitamin D Levels and Health Beliefs

NIH has registered a clinical trial (NCT07535671) evaluating whether a structured patient education program improves health beliefs and medication adherence in patients with Vitamin D deficiency. The 6-month trial will randomize 120 adult hypothyroid female patients with serum Vitamin D below 30 ng/dL to either face-to-face education with brochures and monthly phone follow-ups or standard care. The intervention's effectiveness will be measured using the Medication Possession Ratio and serum 25(OH)D levels.

HEARTS Implementation for Hypertension-Diabetes Multimorbidity, Guatemala, 1,440 Adults

NIH's ClinicalTrials.gov has registered a new clinical study (NCT07536919) evaluating the WHO-developed HEARTS implementation program for comorbid hypertension and Type 2 diabetes. The pragmatic cluster-randomized trial will enroll 1,440 adults across 36 public primary care clinics in Guatemala. Participants are randomized to HEARTS intervention or current standard care, with primary outcomes (blood pressure and hemoglobin A1c) assessed at 12 months.

Virtual Roundtable Promotes STI Prevention Treatment During Awareness Week

The New York State Department of Health hosted a virtual roundtable during STI Awareness Week (April 14-20, 2026) with experts from NYS, NYC, and community organizations to discuss STI prevention strategies, stigma reduction, and available resources. New 2024 data on chlamydia, gonorrhea, and syphilis was added to the state's STI Dashboard. Panelists emphasized the importance of screening, open conversations with providers, and equitable access to sexual health services.